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1. Abstract
Objective 
Tissue engineering aspires to create organs and tissue from autologous cells, which mimic the function
of native tissue as closely as possible. However, before a tissue engineered valve can be implanted,
various experiments on the performance of the valve are necessary. Information regarding the reaction
of a cell  layer to different stimuli  enables the prediction of  the reaction  in vivo.  A minimal invasive
implantation procedure might have effects on the cell layer. The transcatheter valve implantation (TAVI)
is a minimal invasive procedure to implant an aortic valve. Escpecially for older and morbid patients the
minimal invasive approach decreases postoperative morbidity and mortality. Currently available valves
for TAVI are biologic valves with a limited durability. Younger patients in particular would benefit from a
tissue engineered valve with a potentially longer durability and growth potential.
Methods and Material
Aortic  homografts  (n=4)  were  first  decellularized  and  then  recellularized  with  fibroblasts  (FB)  and
endothelial  cells  (EC).  The cells  were harvested from saphenous veins,  which were collected during
aortocoronary bypass operations. After valve recellularization, a TAVI simulation was performed. The
homografts were crimped for 10 min and then expanded using a catheter balloon. A dynamic bioreactor
enabled the simulation of pulsatile flow conditions. The valves were exposed to increasing flow rates
over the period of three days (d1 = 1 l/min, d2 = 1.5 l/min, d3 = 2 l/min). After all processing steps, the
final  testing  samples  were  taken  and  analyzed.  Cell  layer  topography  was  evaluated  with  scanning
electron microscopy (SEM). An immunohistochemial (IHC) analysis enabled the assessment of the cell
layer, structure of the extracellular matrix (ECM) and inflammation reaction.
Results
SEM  evaluation  of  the  samples  after  perfusion  displayed  an  inhomogeneous  cell  layer.  EC  staining
demonstrated a damaged cell layer. The IHC analysis of FB presented a similar result, with the exception
of the ventricular side of the aortic valve leaflet. This part of the leaflet retained more of the earlier
seeded FB. 
Conclusion
The cell layers on the homografts, especially the EC layer, took considerable damage during the crimping
and perfusion procedure. Interestingly, the ventricular side of the aortic valve leaflet seemed to have
sustained less damage compared to the arterial  side.  A tissue engineered construct  for TAVI  has to
withstand  the  strains  of  the  implantation  and  perfusion  process.  Further  studies  are  necessary  to
11
evaluate the damage and to develop a procedure which enables a safe transportation of the tissue-
engineered valve.
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Zusammenfassung
Zielsetzung
Das Ziel von Tissue Engineering ist es, aus autologen Zellen Organe und Gewebe zu entwickeln, die die
Funktionen von nativem Gewebe exakt nachahmen. Bevor eine so entwickelte Herzklappe implantiert
werden kann, müssen Tests zur Evaluation der Leistungsfähigkeit durchgeführt werden. Aussagen zur
Reaktion einer Zelle auf verschiedene Stimuli in vitro erlauben die Vorhersage einer möglichen Reaktion
in  vivo.  Auch  eine  minimal  invasive  Implantationsmethode  hat  eventuell  Auswirkungen  auf  die
Zellschicht.  Die  TAVI  (transcatheter  valve  implantation)  ist  eine  minimal  invasive  Methode,  um eine
Aortenklappe zu implantieren. Vor allem bei alten und multimorbiden Patienten reduziert die minimal
invasive  Implantation  die  postoperative  Morbiditäts-  und  Mortalitätsrate.  Die  zurzeit  erhältlichen
Klappen für die TAVI sind tierischen Ursprungs und deswegen von begrenzter Haltbarkeit. Insbesondere
jüngere Patienten würden von einer durch Tissue Engineering entwickelten Klappe profitieren, da diese
Wachstumspotential sowie potentiell längere Haltbarkeit besitzt.
Methoden und Material
Aorten-Homografts  (n = 4)  wurden  zuerst  dezellularisiert  und  dann  mit  Fibroblasten  (FB)  und
Endothelzellen  (EC)  rezellularisiert.  Die  Zellen wurden  aus  Venae  saphenae  gewonnen,  die  während
aortokoronaren Bypass-Operationen gesammelt wurden. Nach der Klappen-Rezellularisation wurde eine
TAVI-Simulation  durchgeführt.  Die  Homografts  wurden  für  10 min  gecrimpt  und  dann  mit  einem
Katheter-Ballon  aufgedehnt. Ein dynamischer Bioreaktor simulierte pulsatile Flussbedingungen. Über
einen Zeitraum von drei Tagen wurden die Klappen steigenden Flussraten (d1 = 1 l/min, d2 = 1.5 l/min,
d3 = 2 l/min)  ausgesetzt.  Nachdem  alle  Schritte  abgeschlossen  waren,  wurden  die  letzten  Proben
entnommen und analysiert.  Die  Topographie  der  Zellschicht  wurde mit  Rasterelektronenmikroskopie
(REM) evaluiert.  Eine abschließende  immunhistochemische Analyse ermöglichte die Beurteilung der
Zellschicht, der Struktur der extrazellulären Matrix und des Ausmaßes der Entzündungsreaktion.
Resultate
In  der  REM-Ansicht  der  Proben  nach  Perfusion  zeigte  sich  eine  inhomogene  Zellschicht.  Die
immunhistochemische  Färbung  gegen  CD 31  ließ  eine  Beschädigung  der  EC-Schicht  erkennen.  Ein
ähnliches  Resultat  ergab  die  FB-Färbung  (TE-7),  mit  Ausnahme  der  ventrikulären  Seite  des
Aortenklappensegels.  Auf  dieser  Seite waren die zuvor angesiedelten FB in höherem Maße erhalten
geblieben.
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Conclusio
Während des Crimpens und der Perfusion nahm die Zellschicht auf den Homografts, besonders die EC-
Schicht, deutlich Schaden. Auffällig war, dass die ventrikuläre Seite des Klappensegels verglichen mit der
arteriellen Seite weniger beschädigt wurde. Eine mit Hilfe von Tissue Engineering erzeugte Klappe für die
TAVI muss dem Stress, der während der Implantation und Perfusion in vivo auftritt, widerstehen können.
Weitere Studien sind daher notwendig, um den Schaden zu evaluieren und Methoden zu entwickeln, die
einen sicheren Transport der Klappe ermöglichen.
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2. Introduction
2.1. The Heart – Anatomy and Physiology
On the 23rd day the heart of a human embryo starts to beat. Long before the brain and other organs are
functioning,  the  heart  has  already  begun  its  work  (Sacks  et  al.  2009).  The  heart  starts  out  as  a
contracting  tube  and  develops  into  a  well  designed  machine,  whose  beat  accompanies  the  human
throughout his life. During a lifespan of 70 years the heart contracts over 3 x 109 times. 
The  contractions  of  the  heart  are  triggered by  specified  myocardial  cells.  The sinus  node,  which  is
composed of this specified myocardial cells, is part of the cardiac conduction system. It enables specific
expansion of the electric pulses and a guided contraction with maximal ejection fraction, depending on
the current necessity. A full cardiac cycle includes the systole (contraction/ejection phase) and diastole
(relaxation phase) of the heart ventricles (Aumüller 2007). The right atrium fills with venous blood from
the systemic circulation during the systole. Via the tricuspid valve the blood flows into the right ventricle
(RV) and is then ejected into the pulmonary circulation, where the blood is oxygenated. After passing the
lungs,  the blood collects in the left  atrium before the left  ventricle (LV) fills  during diastole.  During
systole, the oxygenated blood is then ejected into the systemic circulation. Due to the higher resistance
in the systemic circulation, the transvalvular pressures on the left side of the heart (atrioventricular and
ventriculosystemic pressure) are 5-8 times higher than on the right side (pulmonary valve: 10 mmHg,
aortic valve: 80 mmHg) (Sacks et al. 2009). To overcome these pressures the myocard of the LV is thicker
than the RV (myocardium LV: 8-12 mm, myocardium RV: 3-5 mm) (Kirsch 2010). During the cardiac cycle
the semilunar and atrio-ventricular valves ensure an unidirectional blood flow (Sacks et al. 2009).  The
mitral  and tricuspid valve coordinate the blood flow from the atria  into the ventricles,  hence atrio-
ventricular  valves.  The  aortic  valve  (AV)  and  the  pulmonary  valve  direct  the  blood  flow  from  the
ventricles into the systemic and pulmonary circulation, respectively (Fig 2-1) (Aumüller 2007). The four
valves compose the valve plane (Schmidt, Thews 1983). The AV forms the centre while the pulmonary
valve lies anterior, the mitral valve posteriolateral, and the tricuspid valve posteriomedial (Mackie 2013).
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2.2. The Aortic Valve 
2.2.1. Macroscopic and Microscopic Structure
The AV is one of two semilunar valves in the human heart. Basically the AV is passive tissue which moves
accordingly  to  the pressure  changes caused by  the contracting  heart.  Its  main  task  is  to  enable  an
unidirectional blood flow as well as reducing flow resistance and increasing flow rate. (Sacks et al. 2009)
Three central elements shape the AV: the leaflets, the annulus and the commissures (Mackie 2013). The
leaflets have a semilunar shape. At the point of contact with the aortic wall  they form a crown-like
structure, the aortic annulus. Although the word “annulus” indicates a round shape, there is no specific
histological structure or anatomic body, which befits this description. The term “annulus” in clinical use
often implies the smallest diameter of the outflow tract between the LV and the aorta. The sizing of a
16
Fig 2-1 The human heart Through the semi-visible myocardium the four heart valves can be seen. The
blue colored myocardium indicates the right ventricular system, including the tricuspid and pulmonary
valve. The red colored myocardium demonstrates the left ventricular system, including the mitral and the
aortic valve.
valve prosthesis as well as the positioning of the prosthesis depends on this “ virtual annulus”, which is a
circular ring limited by the nadirs of the leaflet attachments. (Charitos, Sievers 2013) In the middle of the
free edges of the leaflets the margins thickens and forms the so called “Noduli Arantii” (Misfeld, Sievers
2007). During diastole, the Noduli Arantii form a coadaptation region. On both sides of the Noduli the so
called “lannula”, thin semilunar parts of the valve, extend to the aortic wall where they merge with the
commissures. At the commissures the peripheral edges of the leaflets connect and are attached to the
aortic wall. The lannula also include the adherence surface of the leaflets. During diastole, the leaflets
connect at  this  area and form a tight barrier.  The pocket  shaped load bearing structure,  which lies
between the edges of the leaflets and the connection to the aortic wall, is a thin and nearly translucent
tissue with two different sides. A native heart valve is designed to withstand high pressure and great
flow velocities. The microscopic structure of the single leaflet is one key point for accurate function.
Thee layers form the leaflet: the ventricularis, spongiosa and fibrosa (Fig 2-2 a, b). The ventricularis faces
the bloodstream coming from the LV. It is built of a collagen fibre network and layers of elastin filaments,
which are radially aligned. During systole the elastin fibres seem to reduce the radial strain on the leaflet
(Sacks et al. 2009). The  spongiosa is the middle layer between the fibrosa and the  ventricularis. It is
primarily composed of hydrated glycosaminoglycans (GAG) and proteoglycans. It provides a buffer zone
between the fibrosa and ventricularis to enable shear movement during systole and diastole. The fibrosa
is the thickest layer. Its main components are crinkled Collagen Typ I fibres, which are organized in a
dense network. The fibres are predominantly aligned in a longitudinal direction and for a small part also
radially. Functionally, the  fibrosa is the main load bearing layer. The circumferentially aligned collagen
fibres increase stiffness and strength in this direction. (Jana et al. 2014)
The different histological structures of the three laminae facilitate the adaption of the leaflet to the
physical forces to which the AV is exposed to during a cardiac cycle (Hasan et al. 2013). Moreover, the
cells on the leaflets aid in the correct function of the valve. Native cells on the aortic valve leaflets can be
differentiated  into  valvular  endothelial  cells  (VEC)  and  valvular  interstitial  cells  (VIC).  VEC  build  a
monolayer on the surface of the aortic valve leaflet and have the ability to adapt to different mechanical
forces  and  the  changing  hemodynamic  environment.  Furthermore,  they  regulate  the  complex
coagulation pathway, where they inhibit coagulation and ensure a free blood flow, as well as start the
coagulation pathway when an injury occurs and react to the transmitters in the blood flow. (Butcher,
Nerem 2007) VEC differ in certain qualities from the EC on the aortic wall. While vascular EC are parallel
to  the  blood  flow,  VEC  are  oriented  perpendicularly  (Fig  2-3)  (Butcher  et  al.  2004;  Deck  1986).
Furthermore, a study from Simmons et al. (2005) implies a difference in the gene expression of the VEC
on the arterial and ventricular side. Experiments on porcine VEC show a significantly lower expression of
the genes inhibiting vascular and valvular calcification in the EC of the arterial side.
Studies demonstrate, that VEC retain their ability from the prenatal phase to perform endothelial-to-
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mesenchymal transformation. During the valvulogenesis EC in the endocardial cushion start to migrate
into the valvular interstitium, gradually developing the contractile protein α-SMA and finally turning into
VIC. (Paruchuri et al. 2006) It seems that endothelial-to-mesenchymal transformation provides a part of
the renewal of the VIC in the course of physiologic valve remodeling (Hjortnaes et al. 2015). VIC present
the majority of cells in the valve leaflets. They synthesize, maintain and remodel the ECM. When VIC are
activated by mechanical stress or disease they become myofibroblast-like cells, while in their dormant
state they resemble FB. Myofibroblasts are more contractile and release a number of different proteins
(e.g. cytokines, chemokines, growth factors, ECM elements), when the valve is damaged. Moreover, VIC
can also transform into osteoblast-like cells, which are associated with calcification of the valve. (Zhang
et al. 2015)
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Fig 2-2 Schematic structure of an aortic valve leaflet  (a) displays the leaflet attached to the aortic wall.
The crinkled side is the fibrosa (b), which contains mostly Collagen Typ I fibres, which are longitudinally
aligned.  It  is  the  main  load  bearing  layer.  The  spongiosa  acts  as  buffer  zone  between  fibrosa  and
ventricularis. Its main components are GAG. Its architecture enables a shear movement between fibrosa
and ventricularis. The fibrosa is built from elastin and collagen fibres. During systole the elastin fibres
reduce shear stress on the leaflet.
2.2.2. Pathophysiology
The  causes  for  an  aortic  valve  disease  are  varying.  Degeneration,  rheumatic  fever  and  congenital
deformities are abundant reasons for damages to the AV. At the present day degenerative calcification of
the AV is the most frequent cause for an aortic valve stenosis (AVS) in the developed countries,  while
rheumatic  fever  is  still  the  most  common  reason  for  AVS  in  emerging  and  third  world  countries
(Carabello 2007; Coffey et al. 2016). The calcification process was thought to be a passive, degenerative
disease. But studies show that the process of calcification of the AV is similar to that of atherosclerosis of
the vessels (Otto et al. 1994; Zeng et al. 2016). Hemodynamic forces and common cardiovascular risk
19
Fig 2-3 EC under static  and dynamic conditions The flow direction is  indicated by the arrow at the
bottom. The images (a) and (b) represent vascular endothelial cells, (c) and (d) represent the valvular
endothelial cells. In (d) the perpendicular orientation of the valvular endothelial cells is visible, while in (b)
the  longitudinal  orientation of  the  vascular  endothelial  cells  is  demonstrated.  The  green highlighted
pictures  depict  F-Actin  filament  organization,  which  also  changes  orientation  according  to  the  flow
direction.
factors (i.e. diabetes, hyperlipidaemia, hypertension) seem to play an important role in the development
of an AVS (Simmons et al. 2005; Maganti et al. 2010).
Rheumatic  fever  usually  occurs  a  few  weeks  after  an  infection  with  streptococcus  pyogenes.  The
streptococcus “M protein” and cardiac proteins like Vimentin and Myosin have similar surface protein
domains,  thus creating a molecular mimicry and evoking an antibody response (Coffey et al.  2016).
Although, Tandon et al. (2013) hypothesize that binding of the “M protein” to specific collagen structures
is  responsible  for  the  antibody  activation.  Repeated  subclinical  infections  then  lead  to  fibrosis  and
inflammation, which eventually causes valve stenosis (Fig 2-4) (Coffey et al. 2016).  While degenerative
deterioration of the AV is most common in the older population (prevalence of 12.4 % in the population
> 75 years), children between 5 and 15 years have the highest risk for a first episode of rheumatic fever.
The highest prevalence of a rheumatic heart disease lies between the age of 25 to 45 years (Coffey et al.
2016; Remenyi et al. 2016).
Congenital  malformations  of  the  AV  or  the  leaflets  increase  the  risk  for  an  early  onset  of  valve
degeneration and following AVS. Up to 75 % of the patients with a bicuspid aortic valve develop an AVS
(Furukawa, Tanemoto 2015). The bicuspid aortic valve is the most common congenital heart valve defect
(0.5 - 0.8 % of the newborn children are afflicted) (Coffey et al. 2016). Patients with a bicuspid aortic
valve, which develops into an AVS, often require an invasive correction at an earlier age. The average age
at  surgery  in  these  patients  lies  slightly  below  50  years  (Michelena  et  al.  2008).  Furthermore,  the
bicuspid aortic valve is often associated with complications like AVS, aortic valve regurgitation, dilatation
of the aorta and endocarditis (Furukawa, Tanemoto 2015). 
During the progression of an AVS, the myocardium adapts to the change in transvalvular pressure. The
myocardium of the LV thickens and contractility increases (Bonow et al. 2016). However, the benefit of
these  compensatory  mechanisms  is  limited  and  eventually  a  decreased  diastolic  compliance,
subendocardial  ischemia  and  exhausted  myocardial  contraction  reserve  are  the  consequences.  This
ultimately leads to myocardial fibrosis and reduction of the LV ejection fraction. Diagnosis of AVS proves
to be difficult, due to the lack of symptoms at an early stage. Heart murmurs, which are detected during
a physical examination, are often the first indication for an AVS (Nishimura et al. 2014). Severe AVS often
comes with the triad of dyspnea, angina and syncope. AVS combined with one of these symptoms is a
strong  indication  for  AV  replacement.  Studies  show a  very  poor  outcome for  an  untreated  severe,
symptomatic AVS (1-year-mortality up to 50 %, 5-year-mortality up to 90 %) (Bonow et al. 2016). The
replacement of the AV in an asymptomatic AVS is recommended if the LV ejection fraction is decreased,
the stenosis is severe (peak velocity > 4.0 m/s), or there is evidence for a rapid progression of the AVS
(Nishimura et al. 2014). 
Aortic valve regurgitation is less prevalent than AVS  (Bonow et al. 2016). The patients, which present
with this disease, are younger. Nevertheless, the incidence of a clinical significant regurgitation increases
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with age, peaking at the sixth decade of life. (Maurer 2006) Congenital aortic valve regurgitation is often
associated  with  an  unicuspid,  bicuspid,  quadricuspid  valve  or  a  tricuspid  valve  with  leaflet
malformations. Furthermore infectious endocarditis (IE),  congenital or acquired dilatation of the aortic
root  or  the  ascending  aorta,  rheumatic  fever,  and  systemic  lupus  erythematosus can  also  cause
insufficiency (Maganti et al. 2010).  The normally mild onset and the slow progression of a  congenital
aortic valve regurgitation is in most cases well tolerated for many years  (Bonow et al. 2016; Hoffman
2009). Nevertheless, progressive or severe aortic valve regurgitation leads to gradually increasing systolic
LV dysfunction (Bonow et  al.  2016).  Aortic  dissection or  IE  can cause an acute,  severe  aortic  valve
regurgitation.  These  conditions  are  emergencies  and  surgical  treatment  should  not  be  delayed.
(Nishimura et al. 2014) 
IE has a yearly incidence of up to 10 in 100 000 people and is a rare condition (Cahill, Prendergast 2016).
While the intact valvular endothelium is capable of fending of the daily bacteremia it is exposed to,
conditions like rheumatic fever or valve sclerosis damage the endothelium and thus make is susceptible
to infection. Also, heart valve prostheses increase the risk for an IE. 80 - 90 % of IE are caused by the
gram-positive cocci of the staphylococcus, streptococcus and enterococcus species. Clinical symptoms
for an IE are often unspecific, with fever (90 %) and a cardiac murmur (85 %) being the most common.
Furthermore, evidence for complications like heart failure, stroke or metastatic infection can indicate an
IE. While 50 - 60 % of IE cases can be treated with antibiotics, conditions like heart failure caused by
regurgitation  or  stenosis,  uncontrollable  infection,  sepsis  and  high  risk  of  embolism  are  strong
indications for a surgical treatment. 
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Fig 2-4 Aortic valve stenosis due to rheumatic infection The three leaflets adhere tightly in the periphery
and the effective orifice area is decreased.
2.3. Aortic Valve Disease Treatment
2.3.1. Conservative Treatment
While there is actually no causal conservative therapy for an AVS, it is important to treat comorbidities
like hypertension. Patients with decompensated AS and NYHA IV (angina pectoris and/or dyspnea at
rest) eventually benefit from a treatment with vasodilatators to reduce afterload until surgery. Although,
hyperlipidaemia is a risk factor for AVS, statine treatment does not successfully prevent progression of
an AVS. (Nishimura et al. 2014)
2.3.2. Open Heart Surgery
Open heart surgery with cardioplegia and extracorporal circulation is the gold standard for aortic valve
replacement (Bonow et al. 2016). The sternum is opened via a minimal or total median sternotomy. For
cardio-pulmonary bypass an arterial cannula is placed in the aorta ascendens. The venous cannula is
placed in the right atrium or in the inferior and superior venae cavae, if the patient suffers from severe
tricuspid valve disease or has a cardiac shunt (Duran et al. 1991; Schmid 2014). Via the extracorporal
circulation the core body temperature is lowered to 30-34 °C, if the duration of surgery is expected to
last more than one hour (Schmid 2014). The aorta is cross clamped just under the arterial cannula and
cold cardioplegia is instilled retrograde via the coronary sinus or antegrade via the aorta or the coronary
ostia. For myocardial protection the heart is cooled to minimize the ischemic damage (Duran et al. 1991).
The vent, a cannula to drain blood from the LV, is inserted into the right upper pulmonary vein to ensure
a  blood-free  operation  field  (Schmid  2014).  The  wall  of  the  aorta  is  horizontally  cut  open  at  the
sinotubular junction. In case of an aortic stenosis the calcified leaflets of the valve are removed and
surgical  debridement  is  performed  on  the  annulus.  Abscess  or  fistula  of  the  annulus,  which  are
complications of an IE, often require extensive repair and the use of pericardial patches. The size of the
AV prosthesis is measured intraoperative and the new valve is sewed in. CO2 can be added in the situs
during prosthesis implantation to avoid air embolism. The aorta is closed with a continuous side-to-side
suture. Different valve prostheses are available for valve replacement (see  Chapter 2.4. Aortic  Valve
Prostheses).
In some cases of aortic valve regurgitation it is possible to reconstruct the valve and thus sparing the
patients the risks associated with AV prosthesis (Fig 2-5) (Ch 2.4. Aortic Valve Prostheses). It is important
to evaluate if regurgitation is caused by a dilatation of the aortic annulus or a malformation of the valve
itself. A dilatation of the  aortic annulus with an associated aortic valve regurgitation can be surgically
corrected with a subcommissural annuloplasty or the implantation of a prosthetic ring. Dilatation of the
aortic  annulus after  aortic  valve  repair  is  a  common  reason  for  the  recurrence  of  aortic  valve
regurgitation (Mazine et al. 2016). These findings emphasize the importance of securing the annulus
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during surgery. A prolaps of  the aortic  valve leaflet  is  often associated with a bicuspid aortic  valve.
Different surgical methods are  available for the repair of a leaflet prolaps. Triangular resection of the
prolaps and suture of the median adhesion of  the bicuspid valve shorten and elevate the cusp and
enables a tight adaption. Other methods for the repair of an isolated leaflet prolaps include a cusp
plication at the commissures (Minakata et al. 2004).  Aortic valve regurgitation which is caused by the
perforation of a leaflet can be fixed with a homologous pericardial patch (Mazine et al. 2016). However,
an extensive lesion of the leaflet often requires a valve replacement. Reconstructive surgery of the AV is
becoming more common in isolated aortic valve regurgitation today. Whereas reconstruction in AVS is in
most cases not reasonable. (Schmid 2014).
2.3.3. Transcatheter Aortic Valve Implantation 
Initially,  TAVI  was  intended  for  patients,  who  could  not  undergo  conventional  surgical  aortic  valve
replacement due to their multiple comorbidities. The number of TAVI procedures is steadily increasing.
Evolution  of  the  implanting  technique,  decrease  of  procedure  related  complications  and  increasing
evidence based research are reasons for the increase of TAVI procedures. (Bonow et al. 2016) Long-term
results are still pending, thus making TAVI a procedure which is primarily performed in patients with
contraindications for a conventional aortic valve replacement (Kuck et al. 2015). 
Different surgical access points are possible for the insertion of the catheter for valve implantation. The
transfemoral  implantation  route  is  most  commonly  used (Bonow  et  al.  2016). However,  distinctive
kinking  of  the  pelvine  arteries  or  aorta  as  well  as  severe  peripheral  arterial  disease  may  be  a
contraindication  for  the  transfemoral  implantation.  In  those  cases,  the  valve  can  be  implanted
transapical, transaortal via the ascending aorta, or transarterial via the subclavian or axillary artery. An
interdisciplinary heart team is recommended to evaluate the appropriate access point for a TAVI.
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Fig  2-5  Reconstruction  of  an  aortic  valve  regurgitation (a)  shows  the  layout  of  the  reconstruction
procedure. Just bellow the commissures the patches are applied and sutured in. (b) demonstrates the
intraoperative picture before the reconstruction. The leaflets do not adapt. In (c) the subcommissural
patches are applied and the leaflets adapt now.
In case of a transfemoral access, the femoral artery is punctured and a guiding wire is inserted. A sheath,
which is used to insert the valve prosthesis, is introduced in the femoral artery after dilatation of the
punctuation. The diameter of the sheath decreased during the last years. Large sized sheaths in femoral
arteries,  especially  in  elderly  patients  or  patients  with  severe  atherosclerosis,  increase  the  risk  of
vascular  complications  (i.e.  postoperative  bleeding,  dissection  of  the femoral  artery)  (Fanning  et  al.
2013). A guide wire, which is manually shaped to fit the form of the LV to decrease the risk of injury to
the myocardium, is then advanced into the LV. In case of a severe aortic valve calcification, a balloon
valvuloplasty (dilatation of the aortic valve without implantation of a valve prosthesis) can be performed
before valve implantation. This procedure facilitates prosthesis implantation and expansion (Patsalis et
al.  2013).  The balloon is  usually  smaller than the aortic annulus to minimize the risk of  an annulus
rupture and severe aortic valve regurgitation. The balloon valvuloplasty and the valve implantation are
performed during rapid ventricular pacing. The heart rate is raised to 160 - 220 bpm with a temporary
pacemaker, which is usually implanted in the RV via the jugular or the femoral vein. The rapid movement
of the LV during pacing reduces the LV ejection fraction and facilitates the placement of the balloon as
well as the subsequent positioning of the valve prosthesis. During the balloon valvuloplasty the placing
of  the  balloon  is  monitored  using  contrast-enhanced  X-ray  as  well  as  transoesophageal
echocardiography.  The  coronary  flow  is  monitored  with  repeated  contrast  agent  injection  to  avoid
obstruction.  After  the  balloon  valvuloplasty  the  aortic  valve  prosthesis  can  be  implanted.  Before
inserting the prosthesis through the sheath the crimping procedure is performed. Crimping reduces the
diameter of the prosthesis so it fits the sheath and the vessel diameter. Current valve prostheses have to
stay  submerged  in  a  liquid,  because  of  the  treatment  with  a  fixative.  This  presently  prevents  the
development of a preloaded delivery system, where the valve prosthesis is already crimped. (Alavi et al.
2014)  Furthermore,  the valve prosthesis  deteriorates  when crimped for a  prolonged period of  time
(Kiefer et al. 2011).  The crimper puts equal pressure on the sides of the prosthesis, thus enabling a
symmetric decrease in diameter. Crimping is one particular problem of the TAVI procedure. The crimping
of the prosthesis can damage the leaflet structure and thus can decrease valve durability (Alavi et al.
2014). Depending on the valve type, a balloon is needed to inflate the valve after crimping (Fig 2-6).
Meanwhile,  self  expandable  prostheses  are  available,  which  do  not  require  rapid  pacing  during
implantation (Chap 2.4. Aortic Valve Prostheses) (Fanning et al. 2013). Nevertheless, postdilatation may
be  necessary  due  to  regurgitation  after  the  expansion  of  the  valve  (Abdel-Wahab  et  al.  2014).
Hemodynamic  outcome  and  eventual  paravalvular  leakage  are  assessed  with  transoesophageal
echocardiography and X-ray monitoring (Stortecky et al. 2012).
While  the  transfemoral  approach  can  be  performed  under  light  sedation  and  local  anesthesia,
transapical and transaxillary access requires general anesthesia due to the more invasive procedure. For
a  transapical  access,  a  mini-thoracotomy  has  to  be  performed.  The  cardiac  apex  is  located  with
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echocardiography and the incision is placed at the 5th or 6th intercostal space. Purse string sutures, which
are most commonly used, around the puncture site of the apex both hold the moving heart in place and
facilitate closure of the wound after the procedure (Ziegelmueller et al. 2015). After the preparation of
the operation field the myocardium is punctured and a guide wire inserted. It is important to keep the
wire from entangling itself in the chordae of the mitral valve and eventually cause mitral regurgitation.
Following the save deployment of the wire the sheath can be introduced and the following procedure is
performed analogous to the transfemoral approach. A fragile LV myocardium can increase the risk for a
ventricular rupture or building of a LV aneurysm after transapical device implantation (Stortecky et al.
2012).  For a transaxillary or transsubclavian access the artery has to be surgically dissected.  Delivering
the valve prosthesis via a transaxillary or transsubclavican access may cause cardiac ischemia in patients,
who have received a cardiopulmonary bypass surgery, where the internal mammary artery was used as
bypass graft. The internal mammary artery is a branch of the subclavian artery and dissection of the
vessel, which is a possible  complication of the TAVI procedure, can cause ischemia. (Stortecky et al.
2012)
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Fig 2-6 Transfemoral aortic valve implantation (a) shows the guide wire placed in the left ventricle and
the balloon, which is about to be placed in aortic position. (b) demonstrates the inflation of the balloon.
After valvuloplasty the crimped aortic valve prosthesis is brought into position (c). Afterward the valve is
expanded using a balloon (d).  The position of the prosthesis can be confirmed via transoesophageal
echocardiography and X-ray markers on the deployment device and the valve itself (e).
2.4. Aortic Valve Prostheses
2.4.1. Mechanical Heart Valves 
The main components of a mechanical heart valve (MHV) are either synthetic or nonbiological (Butany
et al. 2003). Especially titanium and pyrolyte (a type of pyrolytic carbon) are frequently used materials
(Gott et al. 2003). These materials have a very long durability, possibly  up to 30-50 years (Ye et al. 2009).
In most MHV, three main components can be distinguished: the occluder, the housing and the sewing
ring. The occluder is the movable part of the prosthesis. Depending on the valve type it can be a ball, a
disc or a leaflet. The housing provides support and fixation for the occluder. The housing of the caged-
ball valves, as the name implies, is a cage, which guides and hold the ball in place. The valves with discs
or  leaflets  require  a  ring  of  titanium  or  pyrolytic  carbon  as  housing,  where  the  moving  parts  are
mounted. The sewing ring enables the implantation of the MHV. The opening and closing of the MHV is
passive and depends on the blood flow as well as the pressure gradient. (Butany et al. 2003) Looking at
the hemodynamic  properties  of  the different  MHV types,  they can be categorized into two groups:
valves with lateral flow patterns such as caged ball valves (Fig 2-7 a) and valves with a more central flow
such as the tilting disc and bileaflet valves (Fig 2-7 b, c)(Yoganathan et al. 2005). The Starr-Edwards caged
ball valve is the only caged ball valve, which is currently used. While it demonstrates good reliability its
hemodynamic properties are unsatisfactory. The pressure drop of a caged ball valve is higher compared
to a tilting disc or bileaflet valve. (Yoganathan et al. 2004) Moreover, its high-profile configuration and
the occluder-induced turbulence are disadvantageous (Dasi et al. 2009) Nevertheless, all MHV generate
flow patterns significantly different compared to a native AV. High velocity and shear stress are part of
these  flow patterns  which  consequently  cause  damage  to  blood  cells.  Low flow regions  caused  by
recirculation increase the possibility of clot formation. (Yoganathan et al. 2005) To decrease the risk of
clot  formation,  especially  in  the  region  of  the  hinges  in  bileaflet  valves,  the  leaflet  edges  and  the
housing,  a  certain  degree  of  insufficiency  upon  valve  closure  is  admitted  to  allow  retrograde  flow
(Butany et al. 2003). Aside from the thrombogenicity caused by abnormal flow patterns, the reduced
hemocompatibility of the used materials is another risk factor for clot formation (Ye et al. 2009). To
prevent thrombus formation a life long anticoagulation therapy is mandatory. Vitamin K antagonists like
warfarin are utilized for this purpose (Eikelboom et al. 2013). 
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2.4.2. Biological Heart Valves 
Different types of biological heart valves (BHV) are available for aortic valve replacement. Autografts are
organs  or  tissue  which are  removed from their  original  position in  the human body  and  placed in
another position in the same body. One example is the Ross procedure. The malfunctioning aortic valve
is replaced with the patient's own pulmonary valve. A homograft is implanted in the pulmonary valve
position. Due to the moderate pressure in the pulmonary circulation, biological valve prostheses in this
position have a extended durability. The pulmonary trunk is able to grow with the patient, thus making it
especially  beneficial  for  very  young  patients.  However,  late  valve  failure  often  requires  repeated
surgeries which are associated with a higher operative risk. (Bloomfield 2002)
Tissue which is obtained from a human body and placed in another human is considered a homograft.
Homografts can be harvested from cadavers, from organ donors or from the explanted heart of a heart
transplant recipient. A study from Fan et al. (2012) which evaluated the bacterial contamination status of
homografts  of  different  origins,  described a  lower contamination rate  for  homografts,  which where
harvested from recipients of a heart transplant. After explantation the homografts were disinfected in an
antibiotic  solution  and  then  either  fresh-wet  stored  at  4 °C  or  cryopreserved  in  liquid  nitrogen.  A
cryopreserved homograft can stay frozen over a prolonged period of time. However, special care must be
taken during the rewarming process to achieve a homogeneous thawing of the complete homograft to
avoid forming of interstitial ice crystals. Crystallization of interstitial water can cause later degeneration.
During fresh-wet storage more donor cells  on the homograft  stay viable.  These residual  cells  might
increase the immunogenic response of the recipient (Gulbins et al. 2003b). Homografts and native aortic
valves were thought to have the same durability. However, a calcification process limits the durability of
homografts. 20 years after implantation, about 30 - 40 % of the homografts are still functioning. The use
of homografts is very restricted today. The considerable drawbacks of these prostheses include their
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Fig 2-7 Different models of mechanical heart valves (a) depicts a caged ball valve (Starr-Edwards). (b)
shows a tilting disc MHV (Medtronic Hall) and (c) displays a bileaflet MHV (St Jude)
limited availability,  the slightly more complex implantation procedure, and limited durability.  (Delmo
Walter et al. 2012; Bloomfield 2002)
Xenografts are valves, which originate from another species. These valves are either manufactured from
bovine pericardium or a whole porcine valve (Pibarot, Dumesnil 2009). There are porcine valves which
are fabricated either with a stent (Fig 2-8 a) or without (Fig 2-8 b).  The word “stent” in regard to a
“stented valve” refers to a frame, which provides mechanical support and an attachment to the aortic
wall  (Sacks  et  al.  2006).  Theory  stated,  that  the absence of  the sewing ring  and stent  enables  the
implantation of larger valves, and therefore improves the effective orifice area. However, the missing
sewing ring raises the complexity of the implantation. (Cohen et al. 2010) Recent studies regarding the
benefits of stentless valves for the patient (e.g. reducing LV mass, better hemodynamic properties, lower
transvalvular gradients) could validate a significant difference compared to stented valves (Kobayashi
2011).  Bovine  valves  are  fabricated  from  flat  sheets  of  bovine  pericardium  (Fig  2-8  c).  During  the
fabrication process, the focus lies on maximizing the opening area during systole and optimizing the
coadaptation area of the leaflets during diastole. This results in improved hemodynamic properties of
the bovine valves  compared to porcine valves (Vesely  2003).  To reduce antigenicity  and to stabilize
against proteolytic degradation, bovine and porcine valve prostheses are treated with glutaraldehyde.
This process cross-links and masks the antigens, thereby reducing the immunologic response  (Badylak
2004). Nevertheless, xenografts and homografts elicit an immune response from the host body (e.g.
Alpha-Gal antibodies against xenografts; cell mediated immune response activated by antigen presenting
cells against homografts) (Badylak, Gilbert 2008; Moroni, Mirabella 2014). This induces an inflammation
reaction, which also contributes to the limited durability of the BHV. Moreover, glutaraldehyde itself
mediates a calcification process which further adds to the restricted life time of a bioprosthetic valve.
(Vesely 2003) Contrary to MHV, BHV do not require a life long anticoagulation thus decreasing the risk
for major bleeding (Brennan et al. 2013).
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2.5. Heart Valve Tissue Engineering
2.5.1. Introduction
About 1 % of neonates are born with a congenital heart disease. More than 30  % of these malformations
affect  the aortic  or  pulmonary valve.  This  establishes a significant demand for artificial  heart  valves
especially for pediatric patients. (Schoen 2011) Currently a dysfunctional heart valve can be replaced
with either a BHV or a MHV. However, there are limits to the possibilities of the valves. Both valve types
lack the possibility for growth, remodel or repair. The replacement of a malfunctioning heart valve in
young patients often requires multiple subsequent valve replacement surgeries.  The combination of
cells, scaffolds and bioreactors enables tissue engineering to overcome the limits of conventional heart
valve prostheses. The ideal tissue engineered valve enables growth, remodeling and even repair of the
valve. Designed from the patient's own cells the thromboembolic potential is minimal and the optimal
hemodynamic attributes do not require anticoagulation. (Sanz-Garcia et al. 2015)
2.5.2. Heart Valve Scaffolds
A  scaffold  is  a  three  dimensional  supporting  structure  which  enables  cell  adhesion,  migration  and
growth. Biocompatibility of the applied scaffold material as well as mechanical integrity and sterilizability
are essential requirements (Jana et al. 2014). Furthermore, a scaffold should facilitate cell nutrition and
allow dynamic changes of its architecture (Dohmen, Konertz 2009). A scaffold can be  fabricated  from
two different sources: a decellularized heart valve scaffold, either of xenogenic or allogenic origin, or an
artificial scaffold, manufactured from synthetic or natural polymers. Artificial scaffold material can be
further classified by their structure, which is either porous, fibrous or hydrogelic. (Jana et al. 2014)
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Fig  2-8  Different  models  of  biological  heart  valves (a)  shows  a  stented  porcine  valve  (Medtronic
Mosaic),  (b)  a  stentless  porcine  bioprosthesis  (Medtronic  Freestyle)  and  (c)  a  stented  pericardial
bioprosthesis (Carpentier-Edwards Magna)
Decellularized Heart Valve Scaffolds
Decellularized heart valves preserve the complex structure of the ECM of a native aortic valve, which is
one possible advantage over artificial scaffolds. Xenogenic and allogenic heart valves are sources for
decellularized  valves.  The  short  supply  on  human heart  valves  is  the  primary  reason  for  the  more
frequent use of xenogenic heart valves, despite their higher antigenic potential. (Jana et al. 2014) The
host body identifies xenogenic and allogenic cell material as foreign and initiates an immune response
(Gilbert et al. 2006).  ECM proteins, however, are shared within the species and are thus tolerated in
xenogenic  species. The  optimal  decellularization  process  removes  the  native  cellular  and  nuclear
material from the valve while the ECM and the ECM proteins stay intact and preserve their functionality
(Khorramirouz et al. 2014). The decellularization process often combines different procedures, including
physical,  chemical  and  enzymatic  treatments.  A  decellularization  protocol  includes  the  physical  or
chemical lysis of the cell membrane, enzymatic or chemical disconnection of the cell-ECM connection
and the removal of any cell debris, which may elicit immunologic responses (Gilbert et al. 2006).
Physical methods for the decellularization include freeze-thaw cycles, agitation and immersion and the
use of pressure (Keane et al. 2015). During the freezing process ice crystals form intracellular, which
rupture  the  cell  membrane  and  induce  cell  lysis.  The  remaining  intracellular  and  membranous
components have to be removed by consecutive processing. (Crapo et al. 2011) The temperature drop
has to be monitored closely to avoid the formation of ice crystals in the ECM as well. (Gilbert et al. 2006)
Aortic  valve  homografts  showed  signs  of  microscopic  and  macroscopic  fissures  after  rapid  thawing
processes,  most likely due to the temperature differences between the outer and inner wall  during
freezing  and thawing processes  (Wassenaar et  al.  1995).  Agitation and immersion of  the sample  in
enzymatic,  chemical  and/or  detergent  solvents  is  a  commonly  used  decellularization  protocol.  The
duration of the process depends on multiple factors, including the strength of the agitation, the type of
enzymatic, chemical or detergent solution, which is utilized, and the thickness and density of the tissue.
(Keane et al. 2015) Pressure can aid in the distribution of decellularization agents into the tissue and
remove the cellular remains from the tissue. Applying pressure gradients during the decellularization of
hollow organs (e.g. blood vessels, intestines, urinary bladder) can be advantageous. (Keane et al. 2015)
Montoya  et  al. (2009)  decellularized  human  umbilical  veins  using  a  convective  flow  protocol  and
compared it to rotary agitation. Immunohistological analysis showed residual cell debris in the samples
which were subjected to rotary agitation. The vessels which were exposed to convective flow at 5 mmHg
and 50 mmHg were free of cells. The circumferential collagen structure stayed intact. However, at higher
pressures (150 mmHg) the basement membrane was disrupted to a certain degree. 
Non-ionic detergents such as Triton X-100 sever lipid-lipid and lipid-protein interactions. Protein-protein
interactions stay intact, thus proteins within tissues maintain their functionality. Triton X-100 is known
for  its  moderate  impact  on  the  tissue  structure  itself.  It  is  widely  used  in  various  decellularization
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protocols. (Gilbert et al. 2006) The valvular structure of an aortic valve stayed intact after 24 h treatment
with Triton X-100. The nuclear material was completely removed from the valve. However, cell remnants
were detected in the attached myocardium and the aortic  wall.  Regarding the ECM, treatment with
Triton  X-100  causes  a  nearly  complete  loss  of  GAG and a  decrease  of  the quantity  of  laminin  and
fibronectine in the heart valve. (Grauss et al. 2005) The loss of GAG highly depends on the tissue, which
is decellularized. While heart valve tissue loses most of its GAG after a 24 h treatment with Triton X-100,
the  GAG  of  the  anterior  cruciate  ligament  stayed  intact  even  after  a  4  day  period  of  processing.
Treatment with Triton X-100 can be a very effective decellularization, but its effectiveness depends on
the tissue, which is processed and the combination with other decellularization methods. (Gilbert et al.
2006)
Ionic detergents like sodium dodecyl sulfate (SDS) and sodium deoxycholate (SD) solubilize cytoplasmatic
and nuclear cellular membranes, but can also cause denaturation of proteins by dissolving the protein-
protein connections. SDS displays a very efficient removal of cell components from tissue, compared to
other detergents. Nuclear remnants and cytoplasmatic protein are also removed. However,  the GAG
concentration and collagen integrity decrease after the use of SDS. SD also exhibits efficient cell removal
qualities, but causes even more disruption in the structure of the native tissue compared to SDS. (Gilbert
et al. 2006) Nonetheless, SDS and SD efficiently remove cells from tissue as well as enable host cell
repopulation after decellularization (Rieder et al. 2004; Khorramirouz et al. 2014).
Enzymatic decellularization includes the processing with proteases (e.g., trypsin), nukleases (e.g. DNase,
RNase) and esterases (phospholipase A2) (Keane et al.  2015).  During the enzymatic decellularization
with trypsin peptide bonds on the carbon side of arginine and lysin are separated if the next residue is
not  proline  (Voet  2002).  Studies  show  different  results  regarding  the  decellularization  efficiency  of
trypsin. While some report a  limited success of cell removal  compared to the decellularization with a
SD 1 %/SDS 1 % mixture (Khorramirouz et al. 2014), others describe a nearly complete cell removal after
a 24 h treatment of the valve with trypsin 0.05 %/EDTA 0.02 % (Schenke-Layland et al. 2003). DNase and
RNase  catalyze  the  hydrolization  of  deoxyribonucleotides  and  ribonucleotide  chains.  During  the
decellularization  process,  they  are  often  utilized  to  remove  residual  DNA  when  the  detergent
decellularization showed incomplete decellularization. (Keane et al. 2015) After the decellularization of
rat aortic valves with SDS 0.1 % for 24 h at 4° C Grauss et al. (2003) added an enzymatic decellularization
step with RNase and DNase to remove any residual substances. They achieved a complete removal of
cells through the whole valve tissue. The elastic laminae as well as the collagen fibres seemed to be
intact. However, fibronectin and chondroitin sulfate were completely washed out from the leaflet albeit
still  present in the base of the valve.  The pancreatic phospholipase A2 hydrolyzes the ester bond of
membrane glycerophospholipids. Wu et al. (2009) demonstrated almost complete cell removal after the
decellularization  of  porcine  corneal  stroma using  a  combination  of  SD 0.5 % and phospholipase  A2
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200 U/ml. The collagen fibres stayed intact as well as a sufficient amount of proteoglycans. 
An important step during the decellularization process is the removal of the residual chemicals after
decellularization. High concentration of chemicals in the decellularized tissue are toxic to the cells and
prevent the host cells from seeding the tissue after implantation or in vitro. (Gilbert et al. 2006) Rieder
et al. (2004) demonstrated the toxic effect of SDS on cells. Porcine pulmonary and aortic valves were
decellularized  with  SDS  0.1 %  for  24 h.  The  residual  cell  material  was  removed  by  subjecting  the
specimen to RNase (100 µg/ml) and DNase (150 IU/ml) treatment for 24 h. The samples were washed
with  M-199  medium  for  24 h  at  4° C.  After  the  decellularization  human  EC  were  seeded  on  the
specimen. Within 24 h no cell attachment was observed but a massive cell lysis took place. Histological
analysis showed no confluent cell layer after 5 days of incubation.
The  efficiency  of  cell  removal  and  the  potential  damaging  of  the  scaffold  tissue  during  the
decellularization process depend to a great extent on the tissue. While using the same decellularization
protocol,  with only  variation in the concentration of  trypsin  (0.5 % vs.  0.05 %),  Grauss  et  al. (2005)
described ineffective  removal  of  cells  from the rat  aortic  valve,  while  Schenke-Layland  et al. (2003)
reported  successful  removal  of  cells  from the  porcine  pulmonary  valve.  The  subtle  changes  in  the
protocol do not fully explain the highly divergent results. It seems the success of a decellularization and
the changes to the ECM differ depending on the tissue source, the composition of the tissue, the density
and  other  factors.  Therefore,  a  tissue  adapted  decellularization  protocol  for  each  different  scaffold
seems necessary, to achieve complete cell removal and reduce damage to the ECM. (Gilbert et al. 2006)
Artificial Heart Valve Scaffolds
Considering the diminishing supply of homograft heart valves for scaffolds and the lack of small-size
homo- and xenografts, artificial heart valve scaffolds can provide a nearly endless supply of valves in all
sizes (McMullan et al. 2006). Decreased immunogenicity and thrombogenicity of artificial scaffolds may
pose advantages as well as control over biodegradability, mechanical properties and durability (Jana et
al. 2014). However, problems arise when the complex architecture and the functionality of the heart
valve have to be copied.  Scaffolds with porous, fibrous or hydrogelic structures are available for the
fabrication of an artificial heart valve with the ability to mimic the ECM and the performance of a native
valve. (Jana et al. 2014)
Porous  scaffolds  provide  an  interconnected  network  of  homogeneous  pores,  which  facilitates  a
continuous sustenance of  nutrients and drainage of  metabolic  waste (Jana et  al.  2014).  The porous
structure  imitates  the  native  ECM,  enabling  interaction  of  cells  with  their  environment
(Dhandayuthapani et al. 2011). The ideal pore size of the scaffold depends on the respective tissue and
cell  (Wei, Ma 2004). Small pores may form a dense network, but they can hinder cell migration and
eventually  impede the building of  large tissue.  Large pores stimulate vascularization of  the scaffold,
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however during in vitro cell seeding these scaffold showed low cell holding and eventually biomechanical
failure  due  to  the  large  unfilled  volume.  (Ghavidel  Mehr  et  al.  2014)  Polyglycolic  acid  (PGA)  and
polylactic  acid were among the first  polymers  used for  tissue engineering (Jana et  al.  2014).  These
materials support cellular adhesion and ECM synthesis. After single leaflet replacement in sheep, they
performed adequately. But due to their high stiffness and rigidity, cell proliferation of the applied cells
could not be achieved. (Jana et al. 2014) Polyhydroxyalkanoates (PHA) are soft elastomeric polymers
with high elasticity and mechanical integrity. Stock  et al. (2000) used polyhydroxyoctanoate (PHO), a
member  of  the  PHA  group,  to  overcome  the  lacking  pliability  of  the  PGA.  Using  the  salt  leaching
technique they manufactured a porous PHO leaflet, which was sutured to a non porous PHO conduit
with a layer of a PGA felt. Accordingly the scaffold was coated with ovine vascular cells and implanted in
sheep for 24 weeks. The examination after 24 weeks revealed an increase in ECM and no thrombus
formation whereas a non seeded control valve showed a severe thrombus formation on all three leaflets
in the doppler echocardiography starting after 4 weeks. PHA are of great interest due to their tunable
mechanical  properties  and  high  biocompatibility.  By  incorporating  different  pendant  groups  the
mechanical properties of the PHA can be varied. For instance, elongating the hydroxyvalerate group of
poly(3HB) leaves the polymer more elastomeric. (Jana et al. 2014) 
Polyglycolic  sebacate  (PGS)  consists  of  an  accordion-like  honeycomb  microstructure.  The  unique
structure of the PGS generates a native-like myocardium tissue and conveys an anisotropy to the cells,
which Engelmayr  et al.  (2008) showed for neonatal  rat heart cells.  The mechanical  and degradation
characteristics of PGS can be controlled by varying the polymerization parameters. Furthermore, the
material displays high biocompatibility. (Jana et al. 2014) The limited water uptake capability of PGS can
be improved by  using  polyethylene glycol  (PEG) and form PGS-co-PEG polymers  (Patel  et  al.  2013).
Coating of the PGS scaffolds with laminin, fibrin, Collagen I, fibronectin or elastin also improved the
cellularity, production of ECM and regulation of the cell phenotype (Sales et al. 2007). Although these
experiments reported positive results, the manufactured 3-D porous scaffolds showed a deficiency in
shape and elastomeric flexibility compared to a native valve. However, new techniques like bioprinting
may enable the fabrication of scaffolds with these characteristics. (Jana et al. 2014)
Fibrous scaffolds mimic the fibre structure of the ECM very closely (Jana et al. 2015). In terms of cell
adhesion, migration, proliferation and differentiation they are superior to non-fibrous scaffolds (Jana et
al. 2014).  Electrospinning is a widely used technique to create fibrous scaffolds. This technique can be
used on most polymers, is ease to handle and versatile. The function of the electrospinning process is
based on the principle of electrostatic. The machine is essentially made of a syringe with a nozzle, a
counter electrode (e.g. metal plate), an electrical field source and a pump. The electrical voltage of the
nozzle and of the counter electrode is different. The polymer is introduced via the nozzle and is exposed
to the voltage difference between the nozzle and the electrode. The polymer globules then assume a
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cone shape, which is caused by the electrical voltage. When the polymer reaches the counter electrode,
the liquid part of the polymer has evaporated and a solid continuous filament is obtained. (Braghirolli et
al.  2014)  The  scaffold  is  built  fibre-by-fibre,  enabling  a  tight  control  of  the  fibre  diameter,  fibre
alignment, macroscopic scaffold geometry and scaffold porosity for cell infiltration of each layer (Capulli
et al. 2016). PGA is a polymer, which is often used in nanofabricated fibrous scaffolds. While the high
mechanical stiffness is a considerable drawback of PGA, biocompatibility and bioabsorbility are favorable
properties of this material. (Jana et al. 2014) The high hydrophilicity of PGA enables a degradation of the
material  in  less  then  4  weeks,  promoting  collagen  and  ECM  production  by  providing  an  effective
environment  and  stimulation  (Atala,  Mooney  1996).  Zünd  et  al. (1998)  seeded FB  on  a  PGA mesh
scaffold. EC, which were seeded on these construct, built a monolayer without the growth of capillaries.
To  improve  biocompatibilty  PGA  meshes  were  dip-coated  with  a  1 %  solution  of  poly(4HB),  a
homopolymer with a reduced degradation rate compared to PGA, thus restricting the degradation rate
of PGA. After 20 weeks of cultivating ovine FB and EC on the scaffold, the results showed a higher ECM
and DNA expression of  the  coated  scaffolds.  (Hoerstrup  et  al.  2000)  The rate  of  degradation  is  an
important factor for the development of a scaffold. Degradation reduces the mechanical properties of
the scaffold, which can be balanced by the ECM production. (Jana et al. 2014) 
While electrospinning has many advantages, the high currents, which are used, limit the usable materials
to polymers  which are  solvent  in  a  conductive  solution (Capulli  et  al.  2016).  This  also includes the
restricted use of natural proteins, due to the denaturating effect of high voltage on the 3-D structure of
proteins.  (Capulli  et  al.  2016)  Rotary  jet  spinning is  a  fabrication method,  which  was  developed to
overcome the shortcomings of electrospinning. Instead of using high voltage, rotary jet spinning uses
centrifugal force to create nanofibres. Natural and synthetic polymers can be mixed to adapt mechanical
properties and degradation rate of the scaffold. (Capulli et al. 2016) A polymer-protein hybrid scaffold
was created by Badrossamay  et al. (2014) using Poly-ε-caprolactone/collagen nanofibres. The scaffold
displayed better mechanical and biodegradation characteristics compared to other hybrid scaffolds or
unaltered polymer scaffolds as well as better cell adhesion.
Hydrogels are characterized by their high water content and the swollen polymer chain networks (Jana
et al. 2014). Their structural similarity to the natural ECM make them usable for tissue engineering and
regenerative medicine (Hoerstrup et al. 2000). Hydrogels promote cell migration and angiogenesis, have
a high water content and enable rapid nutrient diffusion (Bryant, Anseth 2001). The polymer chains,
which the hydrogels are composed of, can be either of synthetic or natural origin. The crosslinking of
hydrophilic  homopolymers,  copolymers  or  macropolymers  defines  the  structural  integrity  of  the
hydrogel.  (Drury,  Mooney  2003)  Hydrogels  can  be  created  using  varying  methods.  Free  radical
polymerization promotes fast reaction and building of the hydrogels. However, the reaction takes place
uncontrollable and results in inhomogeneous characteristics of the hydrogel.  Another method is  the
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conjugate addition reaction, which is based upon the reaction of acrylated monomers, esters or amids
combined with thiols. This method in turn comes with an increased risk of side reactions by competing
nucleophiles from  biological conglomerates, such as living cells. The click chemistry method shows a
mild  reaction  condition  while  retaining  a  high  selectivity,  thus  achieving  better  results  in  hydrogels
compared  to  the  standard  methods.  (Jana  et  al.  2014) Click  chemistry  refers  to  varying  chemical
reactions, which meet the following criteria; the reaction is modular, has a broad range, they produce a
high  yield  and  their  by-products  are  inoffensive  and  can  be  easily  removed.  The  intention  of  click
chemistry reaction is to create selective and modular “blocks” that can be readily applied. The reaction
itself is characterized by its simple reaction conditions, easy to come by starting materials and reagents,
the relinquishment of solvents or only using solvents, which are benign (e.g. water) and easy product
isolation. (Kolb et al. 2001) Different natural and synthetic monomers can be utilized to form hydrogels.
Examples for synthetic monomers are poly(ethylene oxide), poly(vinyl alcohol) (PVA) and polypeptides.
Natural  monomers  include  agarose,  alginate,  chitosan,  collagen,  fibrin,  gelatin,  and  hyaluronic  acid.
(Drury,  Mooney  2003)  The  encapsulation  of  cells  in  a  hydrogel  increases  the  cellular  efficiency by
enhancing the cell adhesion, differentiation and proliferation (Jana et al. 2014).  Flanagan  et al. (2006)
demonstrated  better  cell  surface  coverage  in  collagen-chondroitin  sulfate  hydrogels  compared  to
collagen  only  hydrogels.  A  major  drawback  of  the  hydrogels  is  their  weak  mechanical  stiffness.  In
consequence, the mechanical properties of cell-encapsulated hydrogels have to be enhanced to function
as stand-alone scaffolds. (Jana et al. 2014) The physical properties like stiffness and degree of swelling of
poly(ethylene  glycol)  diacrylate  (PEGDA)  hydrogels  can  be  modified  by  manipulating  the  molecular
weight, the weight fraction of macromer in solution and the crosslinking time (Durst et al. 2011). The
characteristics  of  PVA  hydrogels  are  similar  to  those  of  soft  tissue.  When  physically  crosslinked  by
repeated freeze-thawing cycles the mechanical properties of PVA become more similar to those of a
native porcine valve.  (Wan et  al.  2002) Adding structure and orientation to the hydrogel  is  another
technique to enhance the stiffness. Hockaday et al. (2012) fabricated heterogeneous and cytocompatible
hydrogels  from  PEGDA  using  a  3-D-printing/photocrosslinking  method.  Although,  PEGDA  in  its
unmodified form is known for its non-adhesion properties, porcine aortic valve interstitial cells adhered
and spread on the printed PEGDA hydrogels. Moreover, the stiffness of the modified PEGDA hydrogel
was ten times bigger compared to the original hydrogel.  While bioprinting seems to be a promising
technique  to  build  valve  scaffolds,  challenges  remain  concerning  the  flexibility  and  mechanical
properties of the current valves. The low-viscosity solution, used by modern bioprinters, may not be able
to completely imitate the native heart valve. Although crosslinking can enhance the physical properties
of the valves, it interferes with cell compatibility. These problems are still to be faced and more studies
have to be done to enable in vivo experiments with hydrogel scaffolds. (Jana et al. 2014)
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2.5.3. Bioreactors for Heart Valve Tissue Engineering
The  in vitro conditioning of tissue engineered valves is an essential step towards the development of
functional tissue in vivo. The biomechanical and biochemical conditioning of the heart valve serves two
purposes:  to  enable  the  maturation  of  the  tissue  in  vitro  and  to prepare  the  valve  to  function
immediately after implantation. (Parvin Nejad et al. 2016) A bioreactor can provide these biochemical
and biomechanical stimuli in a controlled environment. When appropriate stimuli are applied on cells,
they can proliferate, differentiate, migrate and align themselves according to the stimulus. Furthermore,
cells  may build,  reabsorb and organize ECM in a desired way.  The change from the original scaffold
material to autologous ECM is also a critical point in the acceptance of the tissue engineered valve after
implantation. (Spoon et al. 2013) Moreover, in vitro testing of durability and function in the bioreactor
can identify structural weaknesses in the valve scaffold prior to implantation or testing  in vivo (Parvin
Nejad et al. 2016). Bioreactors enable control of the environmental parameters of the in vitro testing.
Common in bioreactors is  the regulation of  O2,  CO2,  temperature and nutrient supply. Two types of
bioreactors  can be categorized, depending on the absence or presence of  mechanical  stimuli:  static
bioreactors,  which  give  control  over  the  environment  and  dynamic  bioreactors,  which  additionally
subject the valve construct to biomechanical stimuli. (Parvin Nejad et al. 2016) Dynamic bioreactors can
expose the valve construct to a variety of biomechanical stimuli, including stretch, flexure, shear and
pressure. The different impulses have varied effects on the cells and the valve. While cyclic stretching
can increase cell proliferation, collagen synthesis, stiffness and GAG content, cyclic flexure has a positive
impact on cell migration, collagen synthesis and stiffness. Oscillating fluid shear stress has shown to
increase inflammation resistance, strength, alignment and protection against calcification. (Spoon et al.
2013) Another benefit of the dynamic bioreactor is the capability to evenly distribute cells and nutrient
on a 3-D scaffold. A study conducted by Nasseri et al. (2003) demonstrated that cell seeding on a tubular
polymer scaffold in a rotating bioreactor enabled better nutrient and oxygen distribution and favorable
conditions for cell attachment and tissue growth. The residual medium showed 7 % unattached cells
after 24 h of seeding. After 5 days the inner and outer surface of the tubular construct was covered in a
confluent  layer  of  myofibroblasts.  Cardiac  valve  tissue  engineering  uses  different  types  of  dynamic
bioreactors  for  conditioning.  Spoon  et  al.  (2013)  categorized  three  general  types  based  on  their
objective: flow-based whole valve conditioning bioreactors, which simulate the systole and diastole of a
cardiac  cycle,  strain-based whole valve  conditioning bioreactors,  which aim to perform the diastolic
pressure  and  isolated  cusp  stimulation  bioreactors,  which  put  isolated  leaflets  under  predefined
mechanical stimuli. A flow-based whole valve conditioning bioreactor generally consists of a flow source,
resistance and a compliance module  (Ruel,  Lachance 2010).  A computer  guided pump is  utilized to
generate the pressurized  pulsatile flow which mimics the systole and diastole during a cardiac cycle
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(Spoon et al. 2013). The resistance imitates the blood flow hindrance caused by arteries and capillaries
(Ruel,  Lachance  2010).  In  most  cases  the  compliance  module  consists  of  an  air  filled  chamber,
representing the elastic function of the large arteries (Dumont et al.  2002). A valve chamber, media
reservoir and a gas exchanger are also common in many bioreactors of this type. Advanced bioreactors
also include sensors for flow, pressure, temperature, pO2, pCO2, glucose lactate and valve deformation.
Depending  on  the  construct,  pictures  and  videos  of  the  valve  can  be  taken  using  digital  cameras,
endoscopes or microscopes. (Spoon et al. 2013) Hoerstrup  et al. (2000) designed the first flow-based
bioreactor (Fig 2-9). The design consisted of an air chamber and a medium chamber. The chambers were
separated by a silicone diaphragm, the valve was located in a third chamber. By pumping air into the air
chamber, the medium on the other side was pushed into the valve perfusion chamber and through the
valve. The flow mimicked the systole. A pause in the medium flow changed the pressure gradients, thus
closing the valve leaflets and imitating the diastole. The diaphragm pump generated a flow ranging from
50 to 2000 ml/min, as well as a resulting pressure range from 10 to 240 mmHg. However, the design
denied an independent pressure control (Spoon et al. 2013). Dumont et al. (2002) constructed one of
the first flow-based bioreactors, which enabled independent control over resistance and compliance,
thus giving control over pressure and flow. They varied the compliance by letting air in and out of the
compliance chamber. The resistance was modulated using a clamp on an elastic tube in the system. Both
of these elements create an afterload on the valve by imitating the compliance of the large arteries and
resistance of the capillaries. (Spoon et al. 2013) Hildebrand et al. (2004) developed an improved system,
where  they  incorporated  flow  and  pressure  sensors.  By  installing  a  feedback  control  loop  to
automatically  adjust  the  driving  pressure  and  resistance  the  bioreactor  could  maintain  the  mean
pressure  and  flow  without  a  manual  intervention.  The  bioreactor  designed  by  König  et  al. (2012)
reduced the often unwieldy design of the bioreactors to a smaller form. Their bioreactor was created to
gradually  adapt  an  EC  layer  on  an  aortic  valve  to  simulated  physiologic  flow  conditions.  Earlier
experiments showed a shortcoming of statically incubated EC to acclimate to sudden flow changes. The
EC layer was already damaged by flow rates below physiological thresholds. Three main parts form the
bioreactor: the core, which houses a TeflonTM support unit, the actuation unit and the monitor unit (Fig
2-10). An aortic valve sample can be fixated in the TeflonTM support unit and put into the core element.
The medium is channeled in a laminar flow trough the valve. This establishes sufficient flow and pressure
conditions. The actuation unit creates a pulsatile flow via an air chamber and a membrane. The air,
which is pushed from the actuation unit in the air chamber, moves the diaphragm, which results in a
medium flow. The small size of the bioreactor enables the placement of the bioreactor in a standard
incubator. The avoidance of tubes and screws in this design facilitates sterilization as well as the handling
and assembling of the bioreactor. A monitor unit enables the real time surveillance of the movement of
the valve with an endoscope.
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Strain-based  whole  valve  conditioning  bioreactors  were  created  to  simulate  the  diastolic  pressure
conditions. Mol  et al. (2005) constructed one of the first strain-based bioreactors, the diastolic pulse
duplicator, which put the valve under cyclic pressure in its closed state to mimic diastole. Results from
previous studies demonstrated excellent growth and maturation of tissue engineered blood vessels in
bioreactors that only worked with dynamic wall  straining and without pulsatile  flow (Niklason et  al.
2001;  Seliktar  et  al.  2000;  Kim,  Mooney  2000).  The  dynamic  strain  on  the  valve  was  created  by
repeatedly pressing the surrounding media against the closed valve. Results showed a successful tissue
conditioning  with  the use of  the diastolic  pulse  duplicator.  Initially,  Mol  et  al.  (2005)  estimated the
amount and distribution of the strain on the leaflets using finite element analysis. However, this method
gave no control over the tissue deformation and the monitoring possibilities were limited. Additionally,
the tensile properties of the leaflet changed with the growing ECM and scaffold degradation. These
changes could not be accounted for in the original diastolic pulse duplicator. (Parvin Nejad et al. 2016) To
address these problems, Kortsmit et al. (2009a) installed a control system, which calculated the tissue
strain based on the volumetric deformation of the leaflet. The volumetric deformation accounted for the
changes in volume due to the deformation of the leaflet and was measured using a flow sensor. An
additionally installed feedback loop enabled the adaption of the system to the growing ECM and the
biomechanical changes of the maturing tissue. Using the volumetric deformation, the feedback control
mechanism allowed the evaluation and regulation of the induced deformation of the heart valve leaflets.
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Fig 2-9 A pulsatile bioreactor and schematic overview designed by Hoerstrup et al. (2000) The main
components of this bioreactor are the two chambers (1,2) at the base. The air chamber (1) and the fluid
chamber (2) are separated by a silicone membrane (3). By periodically inflating air into the air chamber,
the membrane is set into motion and the fluid is pumped upwards from the lower compartment (2a)
through a tube (4) into the valve perfusion chamber (2b). The valve can be secured in a second silicone
tube (5), which is removable and enables easy fixation of the valve. The medium flows through a valve
inlet (6) and valve outlet (7) into a medium reservoir. The bioreactor was constructed of three acrylic
glass components, which were fixated using stainless steel screws (8).
(Kortsmit et al. 2009b) A variation of the control system from Vismara et al. (2010) used the compliance
of the scaffold as a parameter for its biomechanical behavior. The compliance was estimated assuming a
linear volume pressure relation. Syedain et al. (2009) bypassed the need for a feedback control system,
when they mounted the heart valve inside a latex conduit. The cyclic injection of culture medium into
the latex tube created a distension on the leaflets and thus a mechanical strain. The stiffer latex tube
dominated the mechanical response and thus the strain experience of the leaflets, which resulted in a
consistent  strain  on  the  valve,  regardless  of  the  changes  in  the  heart  valve  leaflet  during  ECM
maturation.
Bioreactors are also used to put single valve leaflets under predefined mechanical stimuli. This option
enables the analysis of specific mechanical stimuli and their effects on the valve leaflet to establish the
optimal conditions for tissue proliferation and differentiation. (Parvin Nejad et al. 2016) Valve leaflets
can be subjected to a variety of different biomechanical stimuli (e.g. flow, pressure or a combination of
different stimuli) (Spoon et al. 2013). Gould et al. (2012) demonstrated that cyclic strain anisotropy can
enhance the turnover of valvular interstitial cells and α-SMA expression. Furthermore, it influences cell
and collagen fibre to orientate in the direction of the strain. In contrast applying cyclic flexural strain on a
non-seeded PGA/PLLA scaffold resulted in a decreased stiffness and damage to the scaffold architecture
(Engelmayr et al. 2003). In both studies cyclic strain seems to play a role in initiating cell differentiation
and orientation as well as biomaterial conversion (Parvin Nejad et al. 2016). Another study conducted by
Engelmayr et al. (2006) demonstrated a synergistic effect of laminar flow and cyclic flexure on the bone
marrow mesenchymal stem cell mediated tissue formation. Isolated cusp stimulation gives important
information on the influence of  different  mechanical  stimuli  on the cells  and the scaffold  material.
Comparing  these  results  to  the  performance  of  a  native  valve  gives  further  information  about  the
desired behavior of the tissue engineered valve. (Parvin Nejad et al. 2016)
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2.5.4. Cell Sources for Heart Valve Tissue Engineering
Optimal autologous cells for tissue engineering should readily adopt the function of the original cells and
be easy to harvest. Adult as well as progenitor/stem cells are utilized for the recellularization of heart
valve scaffolds. Cells, which are used for heart valve tissue engineering in humans, include mesenchymal
stem  cells  (MSC),  umbilical  cord-derived  progenitor  cells,  valvular  interstitial  cells  and  vascular  EC.
(Spoon et al. 2013)
MSC are multipotent cells, which can be harvested from varying tissue including adipose tissue, the
umbilical cord and cord blood as well as bone marrow (Ugurlucan et al. 2009). When they receive the
adequate stimulus, they can differentiate into phenotypes of a diversity of cells like the connective tissue
of organs, tendons and other mesenchymal cells (Patel, Genovese 2011). A study conducted by Iop et al.
(2009)  demonstrated  successful  in  vitro recellularization  of  decellularized  porcine  heart  valves  with
human bone marrow MSC. The cells formed an EC monolayer and differentiated into FB, myofibroblasts
and smooth muscle cells without pre-seeding differentiation. Weber et al. (2011) showed in a nonhuman
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Fig 2-10 A pulsatile bioreactor for whole valve conditioning designed by König et al. (2012) (1) is the
core, where the TeflonTM support unit and the valve is fixated, (2) the actuation unit and (3) the monitor
unit. The monitor unit allows the insertion of an endoscope and real time surveillance.
primate model, that tissue engineered heart valves, which were loaded and then incubated for 10  min
with bone marrow MSC, displayed a nearly confluent layer of EC and VIC 4 weeks after implantation.
However, cell tracking analysis revealed that none of the seeded bone marrow MSC where still present
on the valve.  Although, these cells are easy to obtain from the bone marrow, the  in vitro cultivation
requires time and the proliferation speed depends most likely on age. Moreover, fibrosis and calcification
processes were noted in stem-cell based treatment with these cells. (Ugurlucan et al. 2009)
The umbilical cord is composed of one vein and two arteries. These vessels, the cord blood and the so
called  “Wharton's  jelly”,  a  mucoid  tissue  which  surrounds  the  vessels,  are  sources  for  endothelial
progenitor  cells  and fibroblast  like  MSC.  (Weber et  al.  2012)  The MSC,  which are  derived from the
vessels, have the capability to differentiate into adipose tissue, EC, cardiomyocytes and osteomyocytes.
A high number of immature stem/progenitor cells can be found in the cord blood. (Ugurlucan et al.
2009)  Schmidt et al. (2006)  used  MSC  harvested  from  the  Wharton's  jelly  as  well  as  endothelial
progenitor cells  accumulated from the umbilical  cord blood to seed a non-woven PGA scaffold. The
valves  were  statically  as  well  as  dynamically  incubated  for  28  days.  Results  showed  a  microscopic
architecture close to that of native valve with EC covering the surface and synthesis of collagen in the
deeper layers. The valve samples, which where put under dynamic stimulation, had several tissue layers
resulting in a more mature tissue formation compared to the static samples. Tissue banks have become
more common in the last couple of years. They process and preserve umbilical cord and blood stem cells
to enable their use for future therapies. (Ugurlucan et al. 2009)
Adult cells, which are used for heart valve tissue engineering, include human vascular EC and human
valvular interstitial cells (Spoon et al. 2013). Yang et al. (2012) seeded human vascular cells harvested
from the saphenous vein on a decellularized bovine pericardial patch and conducted in vitro and in vivo
analysis  in a mouse model.  30 days after implantation,  the immunohistochemical  analysis  showed a
confluent cell layer on the surface as well as differentiation of the cells into EC, smooth muscle cells, and
FB. Schnell  et al. (2001) compared venous to aortic myofibroblasts. They harvested human vascular EC
and myofibroblasts from the vena saphena magna as well as from the ascending aorta.  Cell harvest from
the ascending aorta of a living patient can only be performed during a cardiac surgery. Harvesting cells
from a peripheral vein is less invasive. The human body tolerates the loss of a peripheral vein better than
the loss of an artery. Even if the patient does not undergo cardiac surgery, the vein can be obtained via a
small skin incision. The cells were seeded on a biodegradable polyurethane scaffold and incubated for 6
weeks.  The  mechanical  testing  demonstrated  excellent  stability  of  the  VEC  during  axial  traction
compared to human aortic myofibroblasts. Both cells built a viable, multilayered tissue, while the VEC
created more ECM. Gulbins et al. (2005) seeded human saphenous EC and FB on a complex 3-D model,
an aortic root. They used a special rotation incubator to distribute the cells evenly on the valve and the
leaflets. Results showed a confluent and viable EC layer on the valves. Valves, which were preseeded
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with FB demonstrated a higher content of Collagen IV and laminin, which improved the adhesion of EC.
Table 2-1 gives a short overview of the advantages and disadvantages of each cell type.
Tab 2-1 An overview of the different cell types used in heart valve tissue engineering
Advantage Disadvantage
Mesenchymal stem cells
Can be harvested from various tissues In vitro cultivation takes time
Can differentiate into various tissues Proliferation speed decreases with cell age
Umbilical cord/blood cells
Can differentiate into various tissues Can only be harvested at birth
Young  cells,  which  are  free  of  consequences  of
aging
Currently not available for everyone 
Valvular interstitial cells
Express good behavior seeded on scaffolds Autologous cells are difficult to harvest
Function of cells altered in valvular heart disease
Vascular endothelial cells
Autologous cells are easy to harvest Further investigation regarding the feasibility  and
effectivity is necessary
Good performance on seeded scaffolds
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2.6. Aim of this Study
Currently  available  heart  valve  prostheses  have  some critical  disadvantages.  Apart  from the limited
durability on one side and the need for anticoagulation on the other side the lacking ability for growth
and repair is one of the major drawbacks. A tissue engineered valve would not have these handicaps.
Furthermore, a minimal invasive implantation via the TAVI procedure might even be possible. 
Before we think about implanting a tissue engineered valve into a human body via the TAVI procedure
we must know the reaction of the valve and the cells to this treatment. The tissue engineered valve has
the advantage to be built from the patient's own cells. These cells and the cell layer have to be intact
upon implantation. We wanted to know how these valves and the cells would react to the crimping
process and the perfusion. Currently the creation of a tissue engineered valve takes some time. If the
TAVI procedure critically damages the cell layer the advantages of these valve prostheses (e.g. reduced
thrombogenicity, possible growth, reduced inflammatory reaction) may be for naught. So, how does the
cell layer of a tissue engineered valve reacts to crimping and perfusion? Based on the study performed
by Scheuer et al. (2013)  we expected no major changes in the cell layer on the heart valve.
Human FB and vascular EC were harvested from the vena saphena magna. These cells were seeded on a
decellularized aortic valve. To mimic the physiological conditions of a native aortic valve, the FB were
seeded  first.  The  homograft  itself  demonstrates  favorable  characteristics  as  scaffold.  The  ECM
composition  and  mechanical  properties  of  the  homograft  are  very  close  to  the  native  valve.  The
bioreactor, which was used, enabled the simulation of physiological conditions and gradually increasing
flow rates. To assess the reaction of the cell layer immunohistochemical as well as SEM analysis was
performed and quantitatively evaluated. 
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3. Methods
3.1. Cell Culture
General Conditions
Work with cells was performed under sterile conditions under a laminar work flow. The used solutions
were sterile and heated to 37 °C. The cell culture was incubated at  37 °C, 5 % CO2 content and 95 %
humidity unless stated otherwise. 
3.1.1. Cell Cultivation
EC and FB were isolated from excess veins from coronary bypass operations performed at the cardiac-
thoracic surgery department of the University Hospital of Munich, Großhadern.  All donors signed an
informed consent (see “Appendices 1. Informed Consent”), which approved of the use of the left over
veins for an experimental study. The veins were irreversible anonymized. The regional ethic committee
accepted the use of the anonymous excess vein pieces. 
After the removal of the veins from the patients the residual segments were stored at 4  °C in a storage
solution (M 199 20 ml, penicillin/streptomycin 1 ml) for a maximum of two days. The veins length varied
between 5 and 7 cm. The cells were harvested using a modified method described in previous studies
(Miyata et al. 1991; Bader et al. 1998; van Kooten et al.  1994; Gulbins et al.  2006).  The veins were
cannulized and secured at the cannula on one side with a surgical suture. Next they were rinsed with
15 ml  rinsing solution (M199 194 ml, heparin 5000 IE/ml 1 ml, gentamycin 10 mg/ml 5 ml) to remove
plaques and erythrocytes.  During this  step the tightness of  the veins  was also verified.  The  rinsing
solution was pressed into the vein,  while the other  side  was clamped.  Eventual  leakages of  rinsing
solution would  imply  a  fissure  in  the  vein.  Then  they  were  filled  with  collagenase  solution  EC
(collagenase 240 U 10 mg, human serum albumin 20 % 8 ml) and stored in 200 ml PBS in an incubator
for 30 min. This isolation step dissolved the EC layer. The process was inactivated by rinsing the veins
with 15 ml stopp solution (M199 500 ml, fetal calf serum 20 % 125 ml). The EC solution was collected in a
tube  and  centrifugated  at  500 RPM  for  7  min  at  room  temperature  (RT).  After  centrifugation  the
supernatant  was  removed and  the  cell  pellet  was  resuspended in  5 ml  EC growth medium (ECGM)
(growth medium 500 ml, EC supplement 10 ml, fetal calf serum 6 % 30 ml, penicillin-streptomycin 1 ml).
The solution was transferred to a 12.5 cm2 culture cell flask. 
For FB isolation the collagenase solution FB (collagenase 240 U 20 ml, human serum albumin 20 % 8 ml)
was  used  and  the  veins  were  incubated  for  40 min.  Otherwise  the  FB  isolation  was  performed
analogously to the first isolation step. To increase the FB harvest the veins were horizontally sliced and
the  adventitia  was  removed.  The  venous  tissue  was  separated  into  small  slices  (2 - 4 mm2)  and
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positioned under a cover  slip  (2.5 cm x 2.5 cm) on a  culture dish (A  =  9.6 cm2).  The cover  slip  and
consequently the tissue segments were secured with four drops of sterilized silicone. Finally 2.5 ml FB
growth medium (FBGM) (growth  medium 500 ml, FB supplement 10 ml, fetal calf serum 11 % 55 ml,
penicillin/streptomycin 1 ml) were added to support FB outgrowth. The cell cultivation and proliferation
was conducted in the incubator. The cell growth medium (CGM) was exchanged every second day. As
soon as the cell layer reached confluency, a splitting of the cells was performed. The CGM was removed
and the cell culture was rinsed with PBS. Trypsin at 37 °C was added and incubated for 3 min to break
the cell-to-cell bonds. The according volume of PBS, Trypsin and  stopp solution can be read from the
table (Tab 3-1) below. After controlling the enzymatic treatment with a phase contrast microscope, the
reaction was stopped adding 3 ml stopp solution. The cell/trypsin solution was then pipetted into a 50 ml
tube  and  centrifugated  at  500 RPM  for  7 min  at  RT.  The  supernatant  was  removed,  the  cell  pellet
resuspended in 8 ml CGM and then seeded in a new culture flask (ratio 1:6 in passage 1, ratio 1:3 in
subsequent passages).
Tab 3-1 According volume of PBS, trypsin and stopp solution for cell trypsinization
Flask 12.5 cm2 Flask 75 cm2 Flask 162 cm2
Solution Volume
PBS 6 ml 10 ml 14 ml
Trypsin 1 ml 2 ml 3 ml
Stopp solution 3 ml 9 ml 14 ml
3.1.2. Cryopreservation of the Cells
Cells, which were not immediately used for further experiments, were cryopreserved at the third or
fourth passage. For cryopreservation a method established in previous studies was used (Polchow et al.
2012). 
The cells were first trypsinized as described above. After centrifugation the cell pellet was resuspended
in cryomedium (CGM 1.05 ml, FCS 11 % 0.3 ml , DMSO 0.45 ml, 1.5 ml cryomedium/vial) and stored in a
freezer immediately. The cells were cooled down to the temperature of -80 °C at a rate of approximately
-1 °C/min. For long term preservation the cryovials were then stored in liquid nitrogen at -196  °C after
one week. For reuse of the cells they were thawed. Two cryovials were shortly placed (10 sec) in a 37 °C
water bath. DMSO has a cytotoxic effect, so a fast handling of the cell solution was critical. The cells were
resuspended  in  the  defreezing  solution (CGM  and  fetal  calf  serum  6 %  10:1)  and  centrifugated  at
500 RPM for 7 min at RT to remove the cytotoxic DMSO. The supernatant was removed, the cell pellet
resuspended in CGM and seeded in a cell culture flask.
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3.2. Processing of the Aortic Valve
Aortic valves were thawed, decellularized, stented and reseeded with FB and EC. Following they were
crimped and exposed to physiologic flow conditions in a high flow bioreactor (Fig 3-1).
Samples  for  scanning  electron  microscopic  and  immunohistochemial  analysis  were  taken  from  the
native, the decellularized, reseeded and after perfusion valve.
3.2.1. Removal of the Heart Valves
Aortic homografts from organ donors, which were not suitable for  in vivo implantation, were used for
the in vitro experiment. After explantation the hearts were stored in 700 ml M199 at 4 °C for transport.
The aortic valve was dissected under sterile conditions and stored in three plastic bags to ensure sterile
packaging. The inner bag was filled with 60 ml cryopreservation solution (M199 200 ml, DMSO 22.6 ml).
The valve was enveloped in gauze, placed in the bag and another 100 ml cryopreservation solution were
added. After air removal the bag was sealed. The inner bag was placed in two more bags. The aortic
valve was then stored at -196 °C in liquid nitrogen. A quick freezing process was important to prevent the
formation of ice crystal and damage to the aortic wall. 
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Fig 3-1 Processing of the aortic valve After the decellularization (1. Decellularization) of the native valve
(a) the stent was sutured on the valve (b). Then the dynamic seeding procedure was performed. First the
FB (c) were seeded on the valve, then the EC (d). The valve was crimped for 10 min (e) and dilated (f) to
perform the perfusion study (g)
3.2.2. Thawing
2 l Ringer's solution, in two different containers, each with 1 l, were heated up to 56 °C. Thawing solution
(M199 500 ml, penicillin/streptomycin 1 ml) was warmed up to 37 °C. After confirming the integrity of
the  outer  package,  the  outer  envelope  of  the  frozen  homograft  was  removed  under  non  sterile
conditions.  The remaining  two packages containing  the aortic  homograft  were put in 56 °C Ringer's
solution  for  5-7 min.  The  second package  was removed under  sterile  conditions  and the inner bag
containing the frozen aortic valve was thawed in sterile 56 °C Ringer's solution in a sterile container. After
5-7 min  the  last  bag  was  removed and  the  homografts  were  then  thawed in  sterile  56 °C  Ringer's
solution in a new sterile jar. Following the enveloping gauze was removed and the valves  were put in
37 °C  M199.  Before  cell  seeding  the  homografts  were  stored  in  250 ml  storage solution  AV  (M199
249 ml, penicillin/streptomycin 1 ml) for 24 h. Samples for analysis were taken from the vessel wall.
3.2.3. Decellularization
To remove any residual cell material and debris the decellularization step was conducted. First the fatty
tissue and the remaining myocardial tissue were removed with a scalpel and a surgical scissor. The valve
was then put in 500 ml  decellularization solution (PBS 500 ml, SD 2.5 g, SDS 2.5 g) for 24 h on a 3-D
rotating table at RT. To remove any remaining detergent the valve was rinsed 6 times with PBS for 24 h at
RT respectively. After washing the valves were placed in 250 ml  storage solution decell (M199 500 ml,
Penicillin/Streptomycin 1 ml) for 24 h. 
3.2.4. Stenting and Fixation to a TeflonTM Support Unit
To enable the crimping and expanding process the homograft was fixed in a stent. The compressed
cobalt-chromium (CoCr, NP35N) stent was first expanded using a hegar's dilator to the diameter of the
respective homograft. Then the stent was securely fixed to the vessel with single button sutures at the
top and the bottom. In between the stents were sewed in with less single button sutures (Fig 3-2 a).
Afterwards  the  valve  was  positioned  in  a  TeflonTM frame  (Fig  3-2  b)  and  secured  with  a  single
circumferential  suture to the TeflonTM frame at  the myocardial  part  of  the vessel  (Fig  3-2 c,  d).  The
mounting  on  a  TeflonTM unit  enabled  easier  handling  and  positioning  in  the  bioreactor  for
recellularization.
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3.2.5. Recellularization
For the recellularization of the homografts about 1.5 x 106 cells/cm2 were used. The approximate surface
value of the homograft was calculated assuming the homograft as a cylinder and the valve leaflets as
circles.  This  calculation  was  done  for  each  valve  individually.  The  mean surface  area  of  the  valves
amounted to 43.49 ± 7.8 cm2. This resulted in a mean cell number of 65.23 ± 11.7 x 10 6 cells per valve. A
culture flask 162 cm2 holds approximately 3-3.5 x 106 cells. So the optimal number of flasks for seeding
could be determined. The homografts were first seeded with FB and than with EC. To detach the cells
from the culture flask the trypsination method described in Chap. 2.1.3.  “Culturing and trypsinizing of
the cells“ was applied. After processing the cells they were resuspended in as little CGM as possible to
achieve a high concentration of cells. Before seeding the number of cells was determined following the
method described in  Chap. 4.2. “Cell  counting”.  To achieve a homogeneously distributed cell  layer a
dynamic cell seeding bioreactor (Fig 3-3 a) was utilized. After trypsination and counting the cell/CGM
solution was pipetted onto the valve leaflets  in closed position. The homograft was carefully placed
inside the bioreactor and the bioreactor was completely filled with CGM without cells. Special attention
was given to avoid disturbing the already placed cell/GCM solution on the leaflets. After sealing the lid
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Fig 3-2 Stenting and mounting of the decellularized valve To enable the crimping process a cobalt-
chromium stent was sutured on the outside of  the aortic  homograft (a).  For  easier  handling and to
enable placement in the dynamic seeding bioreactor the homograft was mounted on a TeflonTM unit (b).
The valve was secured with a single circumferential suture in the TeflonTM unit ((c) homograft from the
side, (d) homograft from the ventricular side, remnants of the myocardial tissue are still visible)
on the  bioreactor  eventual  remaining  air  bubbles  were  removed by  gently  pressing  the  down side
located membrane. An outlet with an attached three-way stopcock on top of the lid enabled the removal
of  the  air.  The rotating  bioreactor  enabled a  rotation around the y-  as  well  as  z-axis.  The rotation
facilitated a 3-D distribution of the cells  over the homograft.  To ensure attachment of  the cells  the
reactor's movements were halted during the holding phase for 20 min. The different orientations during
the holding phase ensured a homogeneous spreading. The duration of the running phase of the reactor
took  2.5 min.  The  whole  bioreactor  was  placed  in  an  incubator  for  24 h  at  37 °C/5 % CO2.  After
completing the dynamic seeding phase the remaining cells  in the CGM were counted to assess the
number of cells attached to the valve. Afterward the homograft mounted on the Teflon TM frame was put
under statical incubation in a jar for 6 d at 37 °C/5 % CO2 (Fig 3-3 b). CGM was exchanged every third day.
The procedure was repeated for the seeding of the EC. Samples for analysis were taken of the vessel wall
after recellularization with FB and EC.
3.3. Perfusion Procedure
3.3.1. Crimping
Before  inserting  the  homograft  in  the  bioreactor,  the  crimping  procedure  was  performed.  The
recellularized homografts were detached from the  TeflonTM support unit  and a balloon catheter was
inserted in the middle of the valve (Fig 3-4 a). The mounted valve was positioned in a conventional heart
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Fig 3-3 Recellularization of the aortic valve homograft (a) shows the dynamic seeding reactor. It was
capable  at  rotating  around  its  y-  as  well  as  z-axis  simultaneously.  This  enabled  a  homogeneous
distribution of the cells. To allow attachment in between the 2.5 min running phases, the reactor stopped
for 20 min. This procedure was executed for 24 h. Afterward the valve was incubated in a jar (b) for
another 6 d. 
valve crimper (Fig 3-4 b). A crimper is a device which is used during the TAVI procedure to decrease the
diameter  of  the valve  by  applying  concentric  pressure  on the valve.  The valve  was crimped to the
smallest possible diameter (approximately 7 - 9 mm) with a concentric force of about 10-15 kg (Fig 3-4
c).  Fast  handling of  the valve was critical  to avoid damage from dryness to the cell  layer.  After  the
crimping process the valve was placed in 37 °C CGM for 10 min to simulate the delivery process in vivo
during the TAVI procedure. Finally the valves were expanded again by injecting water into the balloon
catheter. 
Because of better hemodynamic properties the valve was placed in a special designed acrylic glass unit
(Fig 3-4 d). This unit omitted the need to suture the valve to a TeflonTM frame again, which minimized the
necessary handling. An indention on the inside of the acrylic glass unit enabled the sutureless fixation of
the valve. Moreover, the closed sides of the the acrylic glass unit supported a laminar CGM flow. The
TeflonTM frame had open sides . After crimping and fixation of the valve, it was placed in the high flow
bioreactor for perfusion (Fig 3-4 e). 
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Fig 3-4 Overview of the crimping procedure and the acrylic glass unit for mounting in the bioreactor(a)
shows the recellularized valve placed on a balloon catheter. (b) depicts the mounted valve in the heart
valve crimper. The valve was crimped to a diameter of 7-9 mm (c). The valve was then stored in CGM for
10 min at 37 °C. The acrylic glass unit was designed to enable the sutureless fixation and improve the
flow conditions. (d) demonstrates the assembled acrylic glass unit. The placement in the bioreactor can
be seen in picture (e). A white spacer was inserted to guarantee a safe placement in the bioreactor. The
closed sides of the valve enabled a laminar and therefore more physiologic blood flow compared to the
TeflonTM frame, which had open sides.
3.3.2. High Flow Bioreactor and Perfusion
A high flow bioreactor (Fig 3-5 a-c) performed the pulsatile perfusion on the seeded homograft. To copy
a physiologic flow the Berlin Heart EXCOR® system (Fig 3-5 d), a left ventricular assist device (LVAD), was
utilized. This LVAD system uses pneumatic compression to create a pulsatile flow. A membrane separates
an air filled chamber from the blood (or medium) and transfers the pulsatile movements on the blood.
Two valves in the LVAD guarantee an unidirectional blood flow. The LVAD was connected to a computer
guided actuation unit (Fig 3-6 a, b), which created a pulsatile flow. Via the inlet and the outlet of the
bioreactor and silicone tubes the LVAD was connected to the bioreactor (Fig 3-5 d). The homograft was
subjected to  the pulsatile  flow over  a  period  of  three days.  During  these  three days  the  flow was
increased every 24 h. The program started with 1 l/min, then the flow was raised to 1.5 l/min and finally
to 2 l/min. 
To minimize the risk of bacterial or fungal contamination the removable parts of the bioreactor were
kept to a minimum. Altogether seven parts of the bioreactor were movable. The whole body and the
corresponding parts  were gas  sterilizable.  The setup of  the bioreactor  was performed under sterile
conditions. All connections to the open air were sealed with a three-way stopcock and a sterile micro-
filter (pore size 0.22 µm), to allow gas exchange and prevent contamination. The whole bioreactor fitted
in an incubator, thus temperature, gas content and humidity could be controlled. The medium flowed via
the inlet to the homograft. After the reseeding procedure the TeflonTM frame was removed and the valve
was mounted in an acrylic glass unit. The acrylic glass unit minimized the necessary handling of the valve
and ensured a laminar  medium flow through the valve.  The valve  chamber had a round lid,  which
enabled the insertion of the homograft. It was locked with a rubber seal. The long acrylic glass tunnel
connected two compliance cylinders, which mimicked the elastic function of the large arteries. Right
before the compliance cylinders an endoscopic access was located. It provided life video footage of the
performance of the valve (Fig 3-7 a, b). After the connection tunnel two medium reservoir chambers
were placed. A movable wall between these chambers simulated the resistance of the small vessels. Via
a screw the resistance value could be changed. The reservoir chambers provided enough GCM to nourish
the  valve  over  a  period  of  three  days.  This  reduced  the  need  for  medium  exchange  and  thereby
decreased the risk of contamination. After the medium reservoir the outlet was attached, which guided
the medium back to the LVAD. The bioreactor had a CGM capacity of 5 l. It was filled with 2.5 l ECGM and
2.5 l M199. For the duration of the perfusion the whole bioreactor was stored in an incubator. After
perfusion samples were taken from supravalvular, valvular and subvalvular parts of the aortic wall and
from the leaflets. 
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Fig 3-5 The high flow bioreactor which was used for the perfusion phase of the study  Picture (a) shows the
outline of the high flow bioreactor. The medium flows (indicated by the orange arrows) through the inlet (A)
into the bioreactor. A cone shaped tunnel (B) diverts the GCM flow. The homograft is attached to the in- and
outflow (D) of the valve chamber (C). The medium is then guided into the tunnel (F) where the compliance
cylinders (E1 and E2) are attached. Via the endoscopic access (G) a live video can be obtained to monitor the
performance of the valve. In the medium reservoir chamber (H1 and H2) enough medium can be stored to
supply nutrients for the recellularized valve over the period of three days. A movable wall (I) between the
reservoir chambers simulates the peripheral vascular resistance. The outlet (J) guides the medium back to
the attached LVAD. Picture (d) shows the Berlin Heart EXCOR®. It is connected via two silicone tubes to the
outlet and inlet of the high flow bioreactor. Two small arrows indicate the flow direction in the Berlin Heart
EXCOR®. Placing the Berlin Heart EXCOR® in the right direction is important because two valves in the LVAD
direct the flow and create and unidirectional flow of medium.
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Fig 3-7 The closure and opening of the aortic valve during perfusion (a) depicts the closed valve. The
three leaflets can be distinguished. (b) shows the opened valve and the leaflets, which align themselves
at the aortic wall.
Fig 3-6 The control unit and the pump The computer guided actuation unit (a), which set the flow rate,
and an enlarged picture of the pump system, which created the pulsatile flow (b). 
4. Analysis
4.1. Phase Contrast Microscopy
Phase contrast microscopy is an advanced technique compared to microscopy to evaluate the state of
transparent  objects.  When light  travels  through a  transparent  object  changes in  the amplitude and
phase appear.  However,  the human eye can only process  the changes in amplitude.  Phase contrast
microscopy makes these changes visible by manipulating the background light of the sample and the
light, which is scattered by the sample and defines most of the details of the specimen. (Zernike 1942)
For  the monitoring  of  the progress  of  cell  cultivation and proliferation (Fig  4-1 a,  b)  as well  as  the
trypsination process (Fig 4-1 c), phase contrast microscopy was utilized. The cells were examined in a
200x optical magnification. 
4.2. Cell Counting
For cell  counting a Neubauer counting chamber was used (Fig  4-2).  During the trypsination process
250 µl cell suspension were removed to perform cell counting. 50 µl each were diluted 1:2, 1:4 and 1:8
with  trypan blue.  Trypan blue enabled the differentiation between vital  and dead cells.  Due to the
damaged cell membrane, dead cells absorb the blue color while vital cells stay uncolored. (Strober 2015)
The number of cells was calculated according to the following formula:
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Fig 4-1 FB and EC in culture FB (a) can be differentiated from EC by their spindle like form as well as their
tendency to build multilayers, which is shown by their overlapping appendices. EC (b) tend to keep a
rounder shape compared to FB and do not build multilayers. Cells during the trypsination process (c).
After  detaching the cells  from the culture medium they have a round shape and float freely in  the
medium.
4.3. Immunohistochemical Staining 
Immunohistochemical  analysis  was  performed  to  identify  the  different  surface  proteins  and  ECM
proteins within the tissue of the heart valve and the cells. This analysis uses the interaction between
antigens and antibodies to apply color, which can be seen through a microscope. Antibodies, which are
produced from different animal race (e.g. mice, rabbits) bind to a specific, predefined protein. After the
first incubation with the animal antibody, a second incubation was performed. This time an antibody
against the animal antibody, which is linked with the enzyme peroxidase, was applied. After the second
incubation  hydrogen  peroxide  (H2O2) was  added  to  the  sample.  This  triggered  a  reaction  with  the
peroxidase, which finally resulted in a brown-red coloring of the sought proteins. Specific antibodies
were used to identify different cell structures. CD31 identified EC. TE-7 was used for FB. SMC-Myosin and
α-Actin  are  found  in  smooth  muscle  cells.  VE-Cadherin  and  Connexin-43  were  utilized  to  identify
intercellular connections. Collagen IV and Fibronectin were used to label ECM proteins. ICAM and VCAM
are cell adhesion molecules, which are expressed during an inflammatory reaction. 
The procedure can be divided into three phases:  Phase 1 (preanalytical) The tissue preparation. This
includes the fixation, trimming, and embedding of the tissue section. The embedded tissue was cut into
small  sections  with the microtome.  Phase  2 (analytic)  begins with  the deparaffination of  the tissue
sections.  Furthermore,  eventual  preincubation  steps  (e.g.  antigen  retrieval,  blocking  of  non-specific
antigens) and the incubation with the first antibody are conducted. During the final step the tissue was
counterstained with the second antibody and the cover slip was attached. Phase 3 (interpretation) The
results are interpreted and the IHC controls are evaluated. (Ramos-Vara, Miller 2014)
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Fig 4-2 Neubauer counting chamber Looking at a Neubauer counting chamber (a) through the light
microscope, the grid (b) becomes visible. To count the living cells, every non-coloured cell in the space of
one big grid in one of the four corners has to be counted. The dimension of the grid depends on the
Neubauer counting chamber, which is used.
4.3.1. Cell Culture Preparation
For the staining of the cell cultures FB and EC cultures were cultivated in cell culture treated 8-well plates
until  they reached confluency. The medium was removed and the whole plates were put into -80 °C
ethanol 96 % for at least 24 h.
4.3.2. Tissue Preparation
The samples, which were taken from the homograft, were put into formalin 10 % at 4 °C for 10 days to
achieve  a  sufficient  fixation.  Following  the  specimens  were  put  into  paraffin  and  after  cooling  the
paraffin blocks were cut into sections between 5 - 8 µm using a microtome. The paraffin slices were
loaded on a slide and were put in a heater at 40 °C for 24 h to dry.
4.3.3. Deparaffination
The specimen were heated to 55 °C and then repeatedly rinsed with Xylene to remove the paraffin. The
samples were rehydrated by a descending alcohol grade. The descending alcohol series started with
ethanol  96 % followed  by  ethanol  70 %,  50 % and  at  last  30 %.  At  each  alcohol  concentration  the
specimen were incubated for 10 min. Finally the samples were permeabilized with 0.5 % Triton-X in PBS
for 10 min at RT. Before antibody application the specimens were rinsed with aqua destillata and PBS for
6 min each to remove the residual ethanol. 
4.3.4. Antibody Application
The samples were first treated with Triton-X to enable a permeabilization of the cell membrane. Samples
for staining against VE-Cadherin, Connexin-43, Fibronectin and Collagen IV were put under a proteolytic
treatment with protease 10 % for 3 min at RT. This process enabled an intensification of the specific
staining  by facilitating the detection of the tissue antigens (Linnoila, Petrusz 1984). A denaturation of
proteins occurred during the fixation process. To expose the antibody binding sites of the proteins, a
proteolytic  demasking  was  performed.  For  proteolytic  demasking  of  ICAM,  VCAM  and  TE-7,  the
specimen were put into 0,1 mM EDTA buffer (pH=8.0) and boiled for 15 min. Samples were boiled in
10mM Tris/1mM EDTA (pH=9,0) solution for 15 min to demask α-Actin. The staining for Connexin-43,
CD31, SMC-Myosin and VE-Cadherin required a treatment with Target Retrieval solution (pH=6.0) and
boiling for 15 min. Endogenous peroxidase of the cells was blocked with 0.4 % H2O2 in PBS. Following the
samples were incubated for 24 h at 4 °C with primary antibodies, which were diluted according to the
producer information.  After the rinsing with PBS the second antibody, which was linked with horse
radish  peroxidase,  was  applied  and  the  samples  were  incubated  for  10 min.  The  application  of  a
color/H2O2 mixture for 10 min enabled the colorization of the sample. For better differentiation of the
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cell nucleus the specimen were stained with hematoxylin and then rinsed for 2-5 min with deionized
water. Finally aqueous mounting solution was applied and the cover slips were put on the samples. The
stained specimen were observed under the light microscope.
4.4. Scanning Electron Microscopy
Introduction 
Scanning electron microscopy (SEM) uses an electron beam to display the topography of samples. An
electron  source,  a  lanthanum  hexaboride  (LaB6)  cathode,  emits  electrons,  which  pass  through  a
combination of different lenses and scanning coils or deflector plates to create a focused beam. The
deflector or scanning coils deflect the beam in its x- and y-axis to create a scanning raster over the
sample. To avoid interaction of the electron beam with air molecules the scan has to be performed in a
high vacuum. When the electron beam hits the sample, the electrons are reflected and lose their energy.
Three types of radiation are generated: the elastic scattering, which creates high-energy electrons, the
inelastic  scattering,  which  results  in  secondary  electrons,  and  the  electromagnetic  radiation.  These
different  radiations  and  particles  can  be  detected  by  specialized  detectors.  A  map  of  the  surface
topography of the sample can be created from the information on the position of the electron beam on
the sample and the intensity of the emitted radiation/particles. 
SEM analysis  can  only  be  performed on  samples  which  are  vacuum resistant,  dry,  and  conductive.
Therefore, wet samples have to be processed before analysis. The normal drying process often involves a
change of the sample structure. To avoid this, the physical effect of phase transition is utilized. During
critical point drying the status of a substance has the same density in its liquid as well as gaseous phase
under a predefined pressure and temperature.  Under these circumstances the sample can be dried
avoiding the transition from the liquid to the gaseous phase and eventual damage caused by this change.
However, due to the loss of fluid, the sample can shrink and fissures can occur. Non-conductive materials
can be locally charged either negatively or positively during the scanning process. To prevent this, the
sample has to be coated with a layer of a conductive element. In most cases gold is used. The layer has
to be ultra thin to enable a correct scan during SEM. To transfer the gold atoms from the target (gold) to
the sample, a high vacuum and the inert  gas argon are utilized.  A high vacuum is generated in the
sample chamber and the target and the specimen are ionized. The target becomes the negative and the
specimen the positive electrode. Following, argon gas is insufflated into the sample chamber. The inert
gas atoms become ionized and accelerate towards the negatively charged target. Small gold particles are
released from the target and a fine gold dust forms. This dust casts down on the sample and envelopes
the surface. 
57
4.4.1. Fixation
Samples for SEM were stored in FIX II solution (Aqua bidest. 456 ml, glutaraldehyd 43.5 ml, HCl 0.75 ml,
Na-CaCO 5.65 g) at 4 °C for at least 48 h. Next the samples were dehydrated in an ascending alcohol
series (30 %, 50 %, 70 %, 96 %) for 10 min each. During the final step the alcohol 96 % was replaced with
acetone at -20 °C. 
4.4.2. Critical Point Drying and Sputtering
The samples were placed in the specimen chamber and filled with acetone at -20  °C. Afterward the
acetone was gradually  replaced with  liquid  carbon dioxide.  As soon as the acetone was completely
replaced with carbon dioxide, pressure and temperature in the specimen chamber was altered (42 °C,
9.0 MPa) to surpass the critical point of carbon dioxide. At this point carbon dioxide changed from liquid
to gaseous phase without forming a phase boundary. Following, the gaseous carbon dioxide was slowly
released over a period of 30 min. The dried specimens were then put in the sputtering chamber, where a
vacuum was generated. The inert gas argon was added and the samples were exposed to gold ions
(180 sec,  10-5 mbar,  24 °C).  Analysis  of  the  samples  was  performed  with  the  scanning  electron
microscope Evo LS10 from Zeiss.
4.5. Image Evaluation with ImageJ
ImageJ  is  an  open  source  image  processing  program  specifically  designed  for  processing  scientific
images.  ImageJ enabled a quantitative evaluation of  the immunohistochemical  samples.  The surface
covered with cells was measured and the ratio between the covered/not covered surface was calculated.
The immunohistochemical staining for CD 31 and TE-7 were utilized for cell coverage evaluation. This
method  added  a  quantitative  evaluation  of  the  immunohistochemical  samples  to  the  qualitative
evaluation of the coloring.
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5. Results
5.1. Cytology
5.1.1. Phase Contrast Microscopy
Phase  contrast  microscopy  was  utilized  to  observe  cell  proliferation  during  culturing,  trypsination
process and to differentiate between EC (Fig 5-1 a) and FB (Fig 5-1 b). EC show a rather irregular shape.
They have a ball-shaped middle, where the cell nucleus is located, and in some cases tails on the sides.
While FB can grow in overlapping layers,  so called multilayers,  EC form monolayers.  FB are spindle-
shaped. Their elongated body contains the cell nucleus in the middle. 
5.1.2. Immunocytochemical Analysis
To verify the specification of the utilized cell cultures, antibody staining was performed. Staining against
CD 31 and VE-Cadherin indicated EC cultures (Fig  5-2 a,  b).  For a negative control  EC cultures were
stained against TE-7, which remained negative (Fig 5-2 c). FB cultures were stained analogously. Protein
expression of TE-7, Fibronectin and negative expression for CD 31 demonstrated FB cultures (Fig 5-2 d, e,
f).
59
Fig 5-1 EC and FB cultures in phase contrast microscopy EC (a) show a cuboid body with short tails on
the sides. FB (b) have a typical elongated shape and can build multilayers.
5.2. Macroscopic Examination of the Aortic Homografts during Processing
The homografts, which were used for the study had a diameter of 2.28 ± 0.15 cm and a length of 2.38 ±
0.42 cm. Macroscopic inspection after thawing of the homografts displayed no damages (Fig 5-3 a, b).
Remains of the myocardium were still attached to the aorta. The two coronary arteries were severed at
approximately 0.5 – 1.0 cm (Fig 5-3 a, black arrow) on every sample. The homografts had a pink-yellow
coloring. This may be due to the pink color of M199, which was used in many solutions and the medium.
After the decellularization, the homografts lost their pink color and a yellow structure remained (Fig 5-3
c,  d).  The  homografts  stayed  intact  and  well  preserved.  Immunohistological  and  SEM  analysis  was
performed to evaluate the decellularization (see  Chapter 5.3.4. “Homograft  wall  after Crimping and
Perfusion,  Chapter  5.4.4.  “Walls  of  the  Homograft  after  Crimping and Perfusion”). Remnants  of  the
myocardium were dissected  to facilitate  the following recellularization.  The  recellularization process
colored the valve slightly pink (Fig 5-3 e, f). The macroscopic structure of the leaflet and the wall seemed
undamaged and fully functional.
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Fig 5-2 Immunocytochemical staining of a representative EC and FB culture EC specific CD 31 is positive
(a). The intracellular adhesion protein VE-Cadherin expression also demonstrates an EC culture (b). The
negative staining against TE-7 (c) in the EC culture was the control. TE-7 staining is strongly colored,
demonstrating FB culture (d). Fibronectin expression is also highly positive (e). The staining against CD 31
in the FB culture remained negative (f)
5.3. Homograft Topography
For  qualitative  analysis  of  the cell  layer  integrity  and  ECM substance,  SEM analysis  as  described in
Chapter 4.4. “Scanning Electron Microscopy” was performed.
5.3.1. Native Homografts 
The luminal surface of the native homografts after thawing appeared inhomogeneous (Fig 5-4 a). The
surface on the outer wall was covered in a corrugated layer (Fig 5-4 b). Both surfaces alternated between
higher and deeper plateaus, leaving the surface very irregular and undulated. The depths and highs of
the luminal surfaces were smaller. Particles of different size adhered to inner surface (Fig 5-4 a, whites
circles) and were visible on all homografts.
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Fig 5-3 Macroscopic views of the aortic homograft during processing In picture (a) and (b) the valve is
inspected after thawing. No tears or fissures, which may be caused by the thawing process, are visible.
The  arrow  in  (a)  marks  a  coronary  artery.  The  leaflets  are  also  undamaged  and  intact.  After  the
decellularization the valve lost its pink color (c, d). A stent was dilated to fit the valve size (c, d) and
sewed in with single knot sutures (e, f). The structure of the aorta and the leaflets are unscathed after
recellularization (e, f). The valve regained a slightly pink color after recellularization.
5.3.2. Decellularized Homografts 
After  the  decellularization  process,  the  luminal  side  (Fig  5-5  a)  appeared  rougher.  Large  and  small
particles in different shapes adhered to the surface (Fig 5-5 a, white circles). The outer wall showed a
woven-like structure, indicating fibres (Fig 5-5 b). 
5.3.3. Recellularized Homografts
The recellularized surface of the homografts showed an intact, homogeneous cell layer (Fig 5-6 a). The
EC demonstrated the typical cobblestone pattern of their distribution, but no orientation in a distinct
direction. Occasionally, fragments and particles adhered to the surface, but these findings were seldom
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Fig  5-4  SEM  image  of  the  native  homograft  surface  The  luminal  surface  is  covered  with  an
inhomogeneous layer. The whole area appears undulated. Round particles in different sizes adhere to the
surface  (a,  white  circles).  The  undulating  is  more  pronounced  on  the  outer  surface  (b).  These  are
representative images of four independent experiments, each performed with heart valves and cells from
a different donor. 
Fig  5-5  SEM  image  of  the  homograft  surface  after  decellularization The  luminal  surface  appears
rougher and more irregular (a). Particles in long shapes are attached to the surface (a, white circles).
Fibres in a woven structure define the outer wall of the homograft (b). These are representative images
of four independent experiments, each performed with heart valves and cells from a different donor. 
and are most likely artifacts, which occurred during SEM processing. One sample displayed tears in the
otherwise intact cell layer (Fig 5-6 c). Reason for these fissures was most likely the manipulation during
the processing for SEM imaging. The outer side of the wall was also covered with cells (Fig 5-6 d). The
distribution of the cell layer was not as homogeneous as on the inner side. Deep tears broke the cell
layer in which the fibre structure of ECM was visible.
5.3.4. Wall and Leaflet of the Homografts after Crimping and Perfusion
Wall
For SEM analysis the aortic homograft was divided into four sections: The supravalvular, valvular and
subvalvular part of the aortic wall and the valve. 
Large patches of a cell layer covered most of the supravalvular wall surface. In between, fissures and
cracks were visible. Occasionally, the fibre structure of the ECM or another cell layer was visible. Dumps
on the layer indicated cell nuclei. However, a cobblestone pattern was not identified. Fragments and
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Fig 5-6 SEM image of the homograft after recellularization A confluent and homogeneous cell layer
covers the surface of the aortic wall (a). The higher resolution of the image shows a cobblestone pattern,
which is characteristic for EC (b). The ruptures (c, white arrows) developed most likely during drying. On
the outer wall a layer of cells is visible (d). Occasionally deep tears occurred, in which the fibre structure
of  the  tissue  was  visible.  These  are  representative  images  of  four  independent  experiments,  each
performed with heart valves and cells from a different donor. 
particles adhered to the surface. The amount of these particles varied between the samples.  
Parts of the walls of the valvular part of the vessel were also coated in a layer. Although it was not as
even as the layer of the recellularized valve. A cobblestone structure was also not visible. Fragments in
different sizes and shapes were scattered all over the specimen. The amount of fragments differed from
sample to sample. Whole cell layers were teared off the wall. The uncovered areas exposed underlying
cell layers and parts of the ECM (Fig 5-7 c, d). 
The  surface  of  the  subvalvular  specimen varied  to  a  certain  extend.  Two samples  demonstrated  a
structure, which resembled a cobblestone pattern and indicated an EC layer (Fig 5-7 e, white circle).
However, part of the cell layer was ripped off (Fig 5-7 e, white arrows). Another sample's layer was torn
(Fig 5-7 f). Elongated cells, which indicated FB, were disrupted and parts of the filamentous ECM were in
view.  Particles  of  different  sizes  were  scattered  over  the  surfaces.  Quantities  of  particles  were
inhomogeneously distributed over the surface.
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Fig 5-7 SEM image of the aortic wall after crimping and perfusion  Supravalvular (a, b), valvular (c, d)
and subvalvular (e, f) samples. The side of the supravalvular wall which faces the bloodstream is covered
by a cell layer (a). Multiple fissures permeate this layer. Through these ruptures other cell layers and to
some extend ECM are  visible.  Particles  of  different  sizes  are  scattered  all  over  the  surface  (b).  The
valvular wall displays similar findings. A large cell layer (c, white arrows) is detached from the underlying
tissue. Cell remnants are scattered over the layer (d). A part of the cell layer in (e) form a cobblestone
pattern (e, white circle). A wide cell layer scales off from the layer below in this part of the wall as well (e,
white arrows). Longitudinally shaped cells, which only partially demonstrate a homogeneous alignment,
cover the surface of the subvalvular wall part (f). Fissures can be found all over the area (f, white arrows).
These are representative images of four independent experiments, each performed with heart valves and
cells from a different donor.
Leaflet
The arterial and ventricular sides of the leaflet were analyzed. However, due to processing after crimping
and perfusion there was no reliable technique to differentiate arterial and ventricular sides. The leaflets
surface was mostly covered in a cell layer. Small fissures and cracks appeared all over the surface. Three
different samples demonstrated a partial cell layer (Fig 5-8 a, white circle), which could be classified as
cobblestone  structure  and  indicated  partial  coverage  with  EC.  The  FB  coverage  of  the  surface  was
inhomogeneous. 50 % of the samples showed a smooth surface. The distinct shape and cell nuclei of
some of the cells was apparent (Fig 5-8 b, c). On the other half, the cell layer was partially torn and the
ECM underneath was visible (Fig 5-8 d). Cell remnants in different amounts were attached to the surface
of every sample. 
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Fig  5-8  SEM  image  of  the  aortic  valve  leaflets  after  crimping  and  perfusion  The  sample  (a)
demonstrates a structure, which can be classified as cobblestone pattern (a, white circle) and indicates an
incomplete coverage which EC. The dotted white line roughly outlines the borders of the cell layer. All
samples were covered with a FB layer. The spindle form of the FB can be seen in (b). The FB layer was in
some case less continuous (c). Parts of the layer are disrupted and the ECM beneath shows (d). These are
representative images of four independent experiments each performed with heart valves and cells from
a different donor. 
5.3.5. Summary of SEM Analysis
TABLE 5-1: SUMMARY OF SEM RESULTS
Process stage Cell layer integrity
Native o
Decellularized homografts FBL --- / ECL ---
Recellularized homografts ECL +++
Homografts after crimping 
and perfusion
supravalvular FBL ++-/ ECL ---
valvular FBL +-- / ECL ---
subvalvular FBL ++- / ECL +--
leaflet FBL ++- / ECL +--
Key: o = cell layer not definitive discernible, FBL = fibroblast layer, ECL = endothelial cell layer, --- = 0-30  %
cell layer cover, +-- = 30-60 % cell layer cover, ++- = 60-90 % cell layer cover, +++ = 90-100 % cell layer
cover
5.4. Immunohistochemical Analysis
5.4.1. Native Homografts
CD 31 (Fig 5-9 a) and TE-7 (Fig 5-9 b) protein expression was negative for a confluent cell layer on the
surface of the wall  samples after staining. TE-7 stains were moderately colored in a band along the
tunica  intima of  the  aortic  walls  in  50 % of  the  specimen.  Although  positive,  this  colorization  only
occurred within the wall and not on the surface. The staining against the intercellular adhesion proteins,
Connexin 43  and  VE-Cadherin,  was  negative.  ICAM  and  VCAM  expression  was  also  negative.  The
immunohistochemical staining showed positive staining against Collagen IV, SMC-Myosin,  α-Actin and
Fibronectin in the wall of the aorta. Collagen IV and SMC-Myosin (Fig 5-9 c, d) staining showed strong
dyeing in all samples. 
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5.4.2. Decellularized Homografts
The decellularization process removed the cells on the aortic wall surface. Staining against CD 31 (Fig 5-
10 a) and TE-7 (Fig 5-10 b) proteins were negative on the wall's surface.  The staining against the ECM
proteins (α-Actin, Collagen IV, Fibronectin, SMC-Myosin) (Fig 5-10 c, d) were positive, which indicated at
least a partial preservation of the ECM.
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Fig  5-9 IHC  staining  of  a  representative  native  homograft cell  nuclei  staining  with  hematoxylin
Occasional staining against CD 31 appears on the samples (a, black circle), but no confluent cell layer is
visible. The broad band of color (b, dotted line) displays the TE-7 staining in the tunica intima of the
aortic wall. In (c) the red color indicates a strong reaction against Collagen IV antibodies. SMC-Myosin is
also highly colored within the aortic wall (d). 
5.4.3. Recellularized Homografts
After the recellularization the staining against CD 31 showed a strong reaction (Fig 5-11 a). The red-
brown staining covered the surface of all samples. The staining against TE-7 demonstrated a confluent FB
layer underneath the EC layer (Fig 5-11 b). CD 31 and TE-7 staining was positive on all samples. The
intercellular adhesion proteins (Connexin 43, VE-Cadherin) colored slightly on 100 % of the samples (Fig
5-11 b, c).  The coloring of ICAM (Fig 5-11 e), a protein which mediates inflammatory response, was
positive in all samples, while the staining against VCAM was negative (Fig 5-11 f). SMC-Myosin showed a
reaction in the deeper layer of the walls, while Collagen IV also demonstrated a colorization near the
surface in 50 % of the specimen (Fig 5-11 g, h). The staining showed a confluent cell layer. 
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Fig 5-10 IHC staining of a representative homograft after decellularization cell  nuclei staining with
hematoxylin. After decellularization no cells were detectable on the surface of the wall, which faces the
blood stream. CD 31 staining is negative (a). In (d) a few scattered cell nuclei are visible in the deeper
layer of aortic wall. TE-7 proteins are stained in the deeper layer of the aortic wall, but staining against
TE-7 is not visible on the surface (b). The staining against Collagen IV (c) and SMC-Myosin (d) is highly
positive.
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Fig 5-11 IHC staining of  a representative homograft after recellularization  cell  nuclei  staining with
hematoxylin.  The staining against  CD 31 demonstrates a strong reaction.  The red layer on the wall
surface (a) shows a confluent EC layer, which is visible on all samples. TE-7 staining verifies a FB cell layer
on all samples (b). The black arrows in (b) mark EC on top of the FB layer. The intercellular adhesion
proteins Connexin 43 (d) and VE-Cadherin (d) color in a faint red layer on the surface of 100  % of the wall
samples. ICAM (e) also demonstrates an expression on all samples, while VCAM (f) expression is not
detected on any sample. The staining for Collagen IV was strongly positive, especially in the tunica intima
of the aortic wall (g). In 50 % of the samples, the protein reaction was also positive close to the surface.
SMC-Myosin expression stained throughout the aortic wall (h). It was positive in 100 % of the samples.
There is no detection of SMC-Myosin in the cell layer on the surface. 
5.4.4. Wall of the Homografts after Crimping and Perfusion
Cell Layer 
The staining against CD 31 displayed no confluent cell layer on the supravalvular, valvular or subvalvular
part of the aortic wall. On one sample about 18 % of the wall  were covered in cells.  However, they
formed only small  patches and no confluent layer (Fig  5-12 a),  which covered the whole wall.  TE-7
expression was visible on all parts of the aortic wall. The FB layer covered more of the aortic wall than
the EC layer (Fig 5-12 b). A mean of 55 % of the aortic wall was covered with FB. On one sample nearly
100 % of the luminal surface was covered with FB. On the three remaining samples about 40 % of the
surface was coated with FB.
Intercellular Adhesion Proteins
The expression of the EC specific VE-Cadherin (Fig 5-13 a) and Connexin 43 (Fig 5-13 b) was positive in
the remaining EC. Although, the samples showed no confluent cell layer compared to the samples after
recellularization, the expression of VE-Cadherin and Connexin 43 was highly colored. 
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Fig 5-12 Cell layer after crimping and perfusion on a representative homograft cell nuclei staining with
hematoxylin. A confluent EC layer is not detected on any of the samples. Although, some red spotted dots
are visible on the wall's inner surface (a, black arrows), a continuous layer can not be discerned. The FB
layers coats about 55 % of the aortic wall (b). One sample displays a nearly 100 % covering (b), while in
the other samples approximately 40 % of the surface is coated.
Inflammation modulatory Proteins
The crimping and perfusion procedure elicited an ICAM expression in the remaining cells on the surface
(Fig 5-14 a). Compared to the expression of ICAM after seeding, the expression remained on the same
level. In contrast, the inflammation protein VCAM was not detectable on the surface (Fig 5-14 b). The
remaining cells (Fig 5-14 b, black arrows) stayed negative for the VCAM expression.
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Fig 5-14 Inflammation reaction after crimping and perfusion on a representative homograft  cell nuclei
staining with hematoxylin. The red staining on the surface is the reaction from the ICAM protein (a). The
remaining  cells  stain  strongly  for  this  protein.  This  reaction  is  detected  on  all  samples  that  still
maintained cells. The inflammation protein VCAM does not show on the samples (b). Although cell nuclei
were colored (b, black arrows) there was no VCAM expression. 
Fig 5-13 Intercellular adhesion molecules after crimping and perfusion on a representative homograft
cell  nuclei  staining  with  hematoxylin.  The  cells,  which  remained  after  perfusion,  show a  distinctive
colorization for VE-Cadherin (a) and Connexin 43 (b).  
Structural Proteins of the ECM
The coloring of Collagen IV increased in strength after crimping and perfusion. Especially the coloring of
the tunica intima intensified. 92 % of the samples displayed a strong red colored band just beneath the
cell layer on the wall's surface (Fig 5-15 a, black dotted line). The staining against Fibronectin was not as
strong as Collagen IV but also increased in the tunica intima (Fig 5-15 c). A faint but distinct reddish band
can also be detected lining the inner surface of the aortic wall.
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Fig  5-15 ECM protein expression  after  crimping  and perfusion  on a representative homograft cell
nuclei staining with hematoxylin. The coloring of Collagen IV intensified after crimping and perfusion (a).
A distinct red band is visible just beneath the cell layer of the aortic wall (a, dotted line). 92  % of the
specimens display this band. Also the staining against Fibronectin reveals this broad line (b). However,
the coloring is not as strong as the Collagen IV colorization.
5.4.5. Leaflet of the Homografts after Crimping and Perfusion
Cell Layer 
Staining against CD 31 on the aortic leaflet after crimping and perfusion showed no EC layer (Fig 5-16 a,
b).  Single  EC  were  scattered  over  the  surface,  but  did  not  form  a  confluent  layer  neither  on  the
ventricular nor on the arterial side of the leaflet. These findings were congruent on all four samples.
TE-7 staining decreased on the arterial side of the leaflet as well (Fig 5-16 d). While 100  % of the wall
were covered in FB after recellularization,  after crimping and perfusion an average of 70 % of the wall
were coated. On the ventricular side of the leaflet about 90 % of the surface were covered in FB (Fig 5-16
c). Three of the samples demonstrated a 100 % cell layer confluency, one showed 60 %. Although cell
nuclei are present in this last sample, the cells did not stain against CD 31 or TE-7 (Fig 5-16 e, f, dotted
line, black circle). The missing staining against TE-7 may be contributed to a staining failure.
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Fig  5-16  Staining  against  CD  31  and  TE-7  on  a  representative  aortic  leaflet  after  crimping  and
perfusion cell nuclei staining with hematoxylin. The cell staining against CD 31 shows no intact cell layer
on the surface of the leaflet (a, b). Single cells are visible (b) but neither of the samples show a confluent
layer,  regardless  of  arterial  or  ventricular  side.  The  staining  against  TE-7  displays  a  red-brown
colorization.  The cell  layer on the ventricular side is confluent (c).  Small  disruptions of the cell  layer
integrity are rare. The arterial side of the leaflet sustained more damage after crimping and perfusion
(d). Interruption of the cell layer are common. This one specimen shows a cell layer which does not stain
for CD 31 (e, area between the dotted lines). Although the cell conglomerate is clearly visible (f, black
circle) it does not stain for TE-7. This is most likely caused by a failure of the antibody staining.
Intercellular Adhesion Proteins
The cells, which were still adherent after crimping and perfusion, did clearly stain for the intracellular
adhesion proteins Connexin 43 (fig 5-17 a, b) and VE-Cadherin (fig 5-17 c, d). Due to fewer cells on the
surface,  the  Connexin  43  reaction  was  not  as  strong  as  in  the  recellularized  samples.  VE-Cadherin
expression, typical for EC, was strongly positive in the remaining EC. The intensity of color did not change
from recellularized state to the crimped and perfused state. 
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Fig 5-17 Intracellular adhesion protein Connexin 43 and VE-Cadherin on a representative leaflet after
crimping  and  perfusion cell  nuclei  staining  with  hematoxylin.  The  staining  against  Connexin 43
demonstrates a deep colorization on both sides of the valve leaflet (a, b). Although, the cell layer is not
confluent and only a few scattered single cells are attached to the surface. The EC-typical VE-Cadherin
shows strong colorization in the remaining EC (c). Remnants of the EC can be found on both sides of the
leaflet (c, d). 
Inflammation modulatory Proteins
ICAM and VCAM expressions were determined to evaluate the inflammation reaction of the cells. ICAM
expression did not increase compared to the recellularized homografts but stayed on the same level (Fig
5-18  a,  b).  Likewise  VCAM  antibody  reaction  remained  negative  (Fig  5-18  c,  d).  A  faint  reddish
colorization in deeper layers of the leaflet may be due to processing artifacts (Fig 5-18 d).
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Fig 5-18 ICAM and VCAM expression on a representative leaflet after crimping and perfusion  cell
nuclei staining with hematoxylin. The cells, which are still attached to the leaflet, show a reaction with
ICAM  antibodies  (a).  The  color  strength  compares  to  those  on  the  aortic  wall  samples  after
recellularization. The cells on the surface of the leaflet do not express VCAM (c, d) and therefore do not
color after antibody application. The reddish color in the deeper layer of the leaflet may be contributed
to processing artifacts. 
Structural Proteins of the ECM
The ECM protein Collagen IV staining showed a deep colorization along the surface of the leaflet (Fig 5-
19). This reaction occurred on both sides of the leaflets. These results were similar to those of the aortic
wall  after  crimping and perfusion.  Compared to the outcome of  the staining  after  recellularization,
Collagen IV expression increased near the surface. The Fibronectin expression was clearly visible as a red
band which covered the surface (Fig 5-19 c, d).
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Fig  5-19  Collagen  IV  and  Fibronectin  expression  on  a  representative  leaflet  after  crimping  and
perfusion cell nuclei staining with hematoxylin. The Collagen IV staining is especially dominant in the
region near  the  surface  of  the  leaflets  (a,  b).  These  results  are  similar  to those  of  the  Collagen IV
expression in the aortic wall. Intensity and area of colorization were similar on both sides of the leaflets.
The staining against Fibronectin (c, d) is also more intense close to the surface of the leaflet. 
5.4.6. Summary of Immunohistochemical Analysis
TABLE 5-2: SUMMARY OF IMMUNOHISTOCHEMICAL RESULTS LISTED IN TABULAR FORM
Protein expression Process stage
Native Decellularized
homografts
Recellularized
homografts
After crimping and perfusion
Wall Leaflet VS Leaflet AS
Cell verification
CD 31 +-- --- +++ +-- +-- +--
TE-7 +-- --- +++ ++- ++- +--
SMC-Myosin +++ ++- ++- ++- --- ---
Intercellular adhesion proteins
Connexin 43 +-- --- ++- ++- ++- ++-
VE-Cadherin +-- --- ++- +-- +-- +--
Inflammation modulatory proteins
ICAM +-- --- +++ +++ +++ +++
VCAM --- --- --- --- --- ---
ECM proteins
Collagen IV ++- +++ ++- +++ ++- ++-
Fibronectin ++- ++- ++- +++ +++ +++
Intracellular structural proteins
α-Actin ++- ++- ++- ++- --- +--
The intensity of the color was categorized. The color strength correlates with the quantity of protein
expression.
Key: --- = no expression, +-- = minimal expression, ++- = moderate expression, +++ = strong expression
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5.4.7. Quantitative Cell Layer Confluency Analysis
Quantitative cell layer confluency analysis was performed as described in Chap. 4.5. “Image Evaluation
with ImageJ”. CD 31 and TE-7 protein expressions were utilized for EC respectively FB proof. Cell layer
integrity of the different parts of the valve and the leaflet were compared. The quantitative analysis of
the FB coating of the wall demonstrated an inhomogeneous distribution. While sample 4 retained nearly
full  coverage of  all  wall  sections (Fig  5-20 b),  the confluency of  the FB layer  on the other  samples
decreased. On the valvular part of sample 2 no cell layer was detected. EC covered less surface of the
aortic wall (Fig 5-20 a). Three samples kept EC on the surface, however, the percentage of covering was
low. There was a distinct reduction of the EC on the surface after crimping and perfusion. The EC cover
of the aortic valve leaflets is similar to the aortic wall (Fig 5-20 c). The FB layer on the leaflet's surface
was better preserved compared to the wall. Further analysis showed a better preservation of the FB on
the ventricular side in three of four samples. 
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Fig 5-20 Percentage of the aortic wall and the leaflet covered by an EC and FB layer (a) The percentage
of EC covering on the aortic wall decreased distinctly after crimping and perfusion . Although, three of the
samples retained part  of  the cells,  the overall  number of cell  covered surface is low, at a maximum
20,6 %. (b) The distribution of FB is very inhomogeneous in between the different samples. While sample
4 retained nearly full FB coverage, the valvular wall section of sample 2 was devoid of any cells. (c) The
results on the leaflet are similar to that on the aortic wall. However, the percentage of FB covering on the
ventricular side was higher compared to the arterial side in three out of four samples.
6. Discussion
At the beginning of this study, we hypothesized that the crimping and perfusion of a seeded aortic valve
would not make a difference in the cell layer integrity. Based on the results of the study by Scheuer et al.
(2013),  who  demonstrated  an  intact  cellular  coating  on  a  polyurethane  valve  after  crimping,  we
conducted our study on aortic valve homografts. Four homografts were thawed and decellularized to
remove cell debris. Afterwards they were reseeded under dynamic conditions with allogenic FB and EC.
To test the stability of the cell layer, the reseeded homografts were crimped and put under pulsatile
perfusion for three days. While Scheuer et al. (2013) only crimped the polyurethane valve, we also put
the valves under perfusion to further investigate the stability  of  the cell  layer.  However,  the results
demonstrated a damage to the EC as well as the FB layer. 
One difference between the study conducted by Scheuer  et al. (2013) and ours was the use of aortic
valve homografts.  Cryopreserved aortic valve homografts were used for the TAVI model.  Although the
supply of homografts is limited, they still present one of the best suited scaffolds for heart valve tissue
engineering, as they preserve the complex valve structure, the optimal hemodynamic properties and are
potentially  less immunogenic than a xenogenic  valve. (Jana et al.  2014) For the investigation of the
stability  of  cell  layers  under  simulated  physiologic  conditions,  homografts  are  the  optimal  scaffold
material. While the immunogenic potential of cryopreserved homografts is low, cryopreservation itself
does not completely remove the cellular components. Yet, most of the cells become apoptotic due to
the damage sustained during  harvesting,  processing and cryopreserving of  the valve (Hopkins et  al.
2009).  Nevertheless,  this  cell  debris  still  maintains  its  antigenic  potential  and  can  induce  an
inflammatory response in the host body (Hopkins et al. 2009; Meyer et al. 2005). Welters et al. (2002)
described  a  strong  human  leukocyte  antibodies  (HLA)  response  to  allografts,  which  were  not  HLA
matched.  Especially  when a second homograft  transplantation was necessary,  HLA titers  were high .
Hopkins et al. (2009) showed that the decellularization of cryopreserved homografts in a sheep model
reduced calcification and improved their  durability.  Meyer  et  al.  (2005)  reported a reduced cellular
immune response to decellularized aortic homografts in a rat model.  Furthermore, over a period of
three  months  decellularized  homograft  elicited  a  decreased  humoral  immune  response  in  humans
compared to non decellularized homografts (Kneib et al. 2012).  Calcification, stenosis and valve failure
can result from an immune response (Hopkins 2006; Zehr et al. 2005). Especially in younger patients the
early structural failure of the valve is a problem. It can be associated with an intense immune response
(Lund et al. 1999). To minimize possible immune response in vivo and to enable recellularization on a
donor-cell free homograft, we removed these cells and cell remnants. We used a mixture of the anionic
detergents SDS and SD to achieve this result. SDS provides excellent cell removal capabilities (Gilbert et
al.  2006).  However,  there  are  mixed  reports  about  the  integrity  of  the  ECM  after  SDS  treatment.
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Whereas Kasimir et al. (2003) reported severe structural alteration of the ECM, Grauss et al. (2003) and
Liao  et al. (2008) demonstrated no loss or disruption of the elastic lamellae and a preserved  collagen
distribution. These contradictory findings may be contributed to the different concentration, duration
times and combination with other decellularization agents. The reports for SD are similar to those of
SDS.  Zhou  et  al.  (2010)  described  better  ECM  preservation  for  SD  compared  to  SDS  and  trypsin  .
Contrary,  Gilbert  et  al.  (2006)  reported  greater  tissue  disruption  after  SD  treatment  than
decellularization with SDS. In our decellularization process we used a solution of SDS 0.5  % and SD 0.5 %.
The  concentration  of  SD  and  SDS  was  between  the  concentration  most  studies  used  for  their
experiments (SDS between 0.1 % and 1 %, SD between 0.25 % and 1 %) (Dijkman et al. 2012; Zhou et al.
2010; Liao et al. 2008). 
To evaluate ECM quality after decellularization, our immunohistochemial analysis included a Collagen IV
staining. The staining showed collagen fibre distribution in the tunica intima and the aortic wall. Liao et
al. (2008)  obtained  similar  results  after  a  decellularization  protocol  using  SDS  0.1 %/RNAse
20 µg/ml/DNAse  0.2 mg/ml.  The  Movats  Pentachrome  staining  performed  by  Liao et  al. (2008)
demonstrated a more intense staining of the fibrosa of the valve leaflet after decellularization with SDS
compared to the decellularization with trypsin and Triton-X. 
We  achieved  almost  complete  cell  removal  in  all  our  samples.  Albeit  in  one  sample  staining  with
hematoxylin colored cell nuclei in the deeper layers of the valve, the surface was cell and debris free.
After the removal of the cells, we conducted a thorough washing process of the homografts to clear any
potential remnants of the decellularization solution. Rieder  et al.  (2004) reported inefficient seeding
attempts on SDS treated aortic homografts compared with SD. While they used a lower concentration of
SDS (0.1 %) they did not perform an intense washing cycle after decellularization. This may contribute to
the low seeding efficiency  of  SDS treated valves  in  this  study.  Cebotari  et  al. (2010)  compared the
cytotoxity  of  three  different  SDS/SD  solutions,  SDS  1 %,  SD  1 %  and  SDS/SD  0.5/0.5 %.  After  the
incubation  of  porcine  pulmonary  valves  in  each  solution  for  24 h  under  continuous  shaking  they
performed altogether 10 washing cycles with PBS. Samples of the washing solution were taken after
each washing cycle. Lactatdehydrogenase was used to test for cytotoxity. The cytotoxity of the SDS/SD
solution decreased significantly after the fifth washing cycle. The solution was nontoxic after the seventh
washing cycle. Furthermore, metabolic testing of the seeded cells demonstrated metabolic activity of
the cells after the second washing cycle in the group using the SD/SDS solution. In our decellularization
protocol  the  valve  were  rinsed  with  PBS  over  7  days  to  remove  cell  remnants  and  potential  toxic
chemicals. Decellularization with a combination of SDS and SD is a well acknowledged technique in our
work group. The decellularized homografts showed no cell remnants and excellent reseeding capabilities
(Haller et al. 2013b; Haller et al. 2013a). 
Decellularization of homografts increases their  durability by decreasing their immunogenic potential.
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However, the acellular ECM cannot regenerate or adapt to varying physiological conditions. Previous
studies showed that an intact autologous EC layer reduced thrombogenicity and inflammation of the
aortic valve leaflets (Lehner 1997). A cell coating can also contribute to ECM production and create a
viable and growing  valve with autologous cells.  The samples of the heart  valves taken after seeding
demonstrated a confluent monolayer of EC, as well as an underlying multilayer of FB. The CD 31 staining
showed a homologous, intact  monolayer of EC visible on the aortic wall surface.  Haller  et al. (2013a)
showed  that  the  EC  layer  of  a  SDS/SD  treated,  reseeded  aortic  valve  stayed  intact  after  low-flow
conditioning.  These findings confirmed the effective seeding on SDS/SD treated valves.  The possible
seeding inhibition by residual SDS which was reported by Rieder et al. (2004) was neither observed in
the study of Haller et al. (2013a) nor in this experiment. The EC were still adherent after conditioning. An
influence of the decellularization with SDS/SD on the adherence of the cells is not very likely.
Previous studies showed that the preseeding with FB increased the adherence of EC on porcine valves
(Schopka et al. 2009; Gulbins et al. 2003a). In our study, we seeded vascular FB on the decellularized
homografts before we applied the EC.  Collagen IV, which is produced by vascular FB, also supports EC
adhesion (Schopka et al. 2009). The cells were harvested from the vena saphena magna. This vein is easy
to access and the vascular cells display excellent quality for heart valve tissue engineering (Yang et al.
2012;  Schnell  et  al.  2001;  Gulbins et  al.  2005).  However,  Butcher et  al.  (2004)  reported differences
between vascular and valvular cells, especially between vascular and valvular EC. While vascular EC align
themselves parallel to the blood flow, valvular EC adjust perpendicular when put under shear stress. The
comparison  of  gene transcription profiles  of  valvular  and vascular  EC under different  hemodynamic
conditions also suggests a distinct difference between the two cell types (Butcher et al. 2006). Vascular
EC  were  used  in  this  study.  These  cells  proved  to  be  shear  stress  resistant  and  able  to  build  a
homologous  cell  layer  on  the surface of  an  aortic  valve  (Haller  et  al.  2013a;  Schopka et  al.  2009).
Nevertheless  the  differences  between  vascular  and  valvular  EC  may  contribute  to  the  adherence
potential  after  crimping and perfusion.  Further  experiments  with valvular  EC ought to  enable  more
insight in these properties and may produce better adherence after crimping. 
A dynamic seeding procedure was performed to achieve homogeneously distributed cells. Nasseri et al.
(2003) demonstrated that a dynamic seeding procedure provided better nutrient and cell distribution on
a 3-D scaffold. Our results showed a multilayer of FB, as well as a cobblestone pattern of EC on the
surface  after  dynamic  recellularization.  Early  perfusion  experiments  demonstrated  that  EC  statically
seeded on  vascular grafts showed poor attachment to the surface once exposed to arterial levels of
shear stress (Inoguchi et al. 2007; Herring 1991; Shindo et al. 1987).  This indicates that abrupt, high
shear stress may damage the EC layer. EC under non flow conditions and EC under shear stress have a
different morphology. While EC under static conditions display a cobblestone pattern in light microscopy,
EC under flow elongate their shape and align themselves parallel to the flow (Butcher, Nerem 2007). The
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elongated shape and the alignment with the blood flow decrease spatial fluctuation of the shear stress
and  reduce  the  maximum  shear  stress  (Noria  et  al.  1999).  Also,  intercellular  adhesion  molecules
reorganize when exposed to shear stress. A study from Noria et al. (1999) demonstrated that adherens
junctions in EC changed their configuration from belt-like in static EC cultures to a localized plaque form.
In addition, other adhesion molecules, including α5β1 Fibronectin receptor and αvβ3 Vitronectin receptor
integrins and the cytoskeletal-associated protein Vinculin and Talin, change their distribution pattern
when  submitted  to  shear  stress  (Girard,  Nerem  1995).  In  our  study  the  decellularized  aortic  valve
showed  an  intact,  confluent  EC  layer  after  dynamic  seeding.  The  EC  layer  displayed  a  cobblestone
morphology as well as high expression of VE-Cadherin. VE-Cadherin is an intercellular adhesion protein,
which plays an important role in cell-cell interaction and in the maintenance of the EC barrier (Corada et
al.  2001).  Crosby et  al.  (2005), demonstrated  in  their  experiment,  that  VE-Cadherin  is  critical  for
vasculogenesis and prevents the disassembly of nascent vessels. The staining against VE-Cadherin was
deeply colored in our experiment. The recellularized wall as well as the residual cells on the aortic wall
after crimping and perfusion exhibited a strong expression of VE-Cadherin. Knowing the importance of
VE-Cadherin for vasculogenesis and accurate EC function, the high expression of this protein suggests a
functioning EC layer. 
After the crimping process we submitted the seeded homograft to shear stress. Although the flow was
gradually increased, the EC layer did not adhere to the FB layer. EC layers which were preconditioned
demonstrated an increased ability to withstand hemodynamic shear stress (Yazdani et al.  2010; Ott,
Ballermann 1995). The lack of a conditioning phase before crimping may have contributed to the lacking
ability  of  the  EC  layer  to  withstand  the  pulsatile  flow.  First  crimping  experiments  did  not  show  a
significant  damage  to  the  cell  layer  after  crimping.  Furthermore,  as  slowly  increasing  shear  stress
improves the EC ability to cope with higher shear stress.  Based on this data, it was reasonable to omit
the precondition phase. Any handling of the aortic valve increases the risk for contamination as well as
increasing the time, which a possible tissue engineered valve needs for completion. Omitting needless
steps  during  the  manufacturing  process  is  mandatory.  However,  our  results  showed a  considerable
decrease of EC on the aortic wall and the leaflet. Further experiments with a precondition phase may
improve the EC adherence. 
Not only the EC layer, the FB layer as well was reduced on the aortic wall and the leaflet. After crimping
and perfusion  the FB covered roughly  55 % of  the  wall's  surface  and 80 % of  both  leaflet  sides.  A
comparison between the FB layer on the ventricular and the arterial side of the aortic leaflet revealed a
difference in cell distribution. While the FB layer on the ventricular side covered about 90 %, the FB layer
on the arterial side coated only 70 %. When we look at the hemodynamics of the aortic valve leaflet
there is a difference between the arterial and ventricular side. The arterial side is subjected to so called
“vortices” or oscillatory shear stress while the ventricular side experiences primarily laminar shear stress
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(Yap et al. 2012a; Balachandran et al. 2011).  In vitro laminar shear stress is a protective factor for EC
against inflammation and oxidative stress (Butcher et al. 2006; Cunningham, Gotlieb 2005). By contrast,
a disturbed blood flow contributes to the formation of  atherosclerosis  (Cunningham, Gotlieb 2005).
These different shear stress conditions may be an explanation for the calcification of the aortic valve
leaflet, which predominantly occurs on the arterial side of the leaflet (Yap et al. 2012b). Our results could
indicate that oscillatory shear  stress damages the FB layer and decreases confluency. The parts of the
aortic valve, which where subjected to laminar flow, retained most of the FB layer. An in vivo experiment
showed that  vascular  FB after  vascular  injury  contribute  to  the formation of  neointima and intimal
hyperplasia (Shi, Tarbell 2011). Depending on whether the FB layer is confluent or subconfluent, they
change their phenotype marker expression and migration potential according to the applied shear stress
(Garanich et al. 2007). Moreover, Grabowski  et al. (1993) showed that a FB monolayer increased the
expression of tissue factor once submitted to shear stress. Considering the fact that FB produce tissue
factor and may induce coagulation, the effect of laminar shear stress and oscillatory shear stress on the
different valve sides should be further investigated.
Studies suggest a possible damage of the ECM and the cell layer by the crimping process. In our studies
the valves were crimped for 10 min. Kiefer  et al. (2011) showed that after the crimping process of a
bovine  pericardial  valve  major  changes  in  the  structural  morphology  of  collagen  fibres  occurred.  A
transcatheter valve (Edwards Sapien bioprosthesis) was crimped for different periods of time ranging
from 1 hour to 1 month. The fragmentation of the valve's leaflet was most prominent in the valve, which
was crimped for 1 month. These significant results indicate that the crimping process of a valve should
be as short as possible. In contrast, numerous studies report no damage to the structural integrity of
tissue engineered heart valves (TEHV) after crimping. Moreira  et al. (2014), Schmidt et al. (2010) and
Dijkman et al. (2012) demonstrated an intact collagen distribution in the valve leaflets of TEHV. Moreira
et al. (2014) crimped the valve for 20 min and received similar results. Although, longer crimping should
be avoided as demonstrated by Kiefer et al. (2011) short crimping periods up to 20 min seem not to alter
the valve's structural integrity. In our study the crimping process lasted up to 10 min. The valve was
subjected in medium during this time. Considering the results from these previous studies, a severe
damage to the ECM of the valve and the wall was not anticipated.
In our research group we demonstrated an intact cell layer after the crimping process (Scheuer et al.
2013). However, another experiment, which was conducted after this study, from our research group
further investigated the crimping process. In this study performed by König et al. (2016) biohybrid valves
(polyurethane  walls,  decellularized  homograft  leaflets)  were  seeded,  then  crimped  and  put  under
perfusion. Samples were taken after crimping and after perfusion. A live/dead assay was conducted.
After the crimping process, an increase in dead cells was observed in the cell layer.  However, after the
perfusion procedure, these cells disappeared and the overall cell count decreased. Like this study already
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anticipated, König  et al.  (2016) reasoned, that the crimping process damages especially the EC layer
severely.  Schmidt et  al.  (2010) found similar  results.  They  crimped a  TEHV which was seeded with
myofibroblasts and EC. After seeding the valves were preconditioned with low flow. However, after the
crimping procedure the EC layer  showed incomplete endothelialization.  This  was contributed to the
surface friction during crimping. Dijkman et al. (2012) demonstrated only a small and local damage on
the layer  of  mesenchymal  stem cells  on a TEHV after  crimping.  Furthermore,  Moreira  et  al.  (2014)
reported similar results about the effects of the crimping process on the EC layer on a tissue engineered
valve. 
In this study we did not take valve samples after the crimping process. Due to the fact, that pulsatile
perfusion had to be performed on the valve after crimping, the leaflets could not be removed. Samples
from the aortic wall may not represent significant samples. Their location at the end of the stent and the
“crimping zone” may produce falsified results. However, the issue of the crimping damage on the cell
layer has yet to be resolved and further investigation is clearly necessary.
We were first to examine the effect of perfusion after crimping on the EC layer. Although the limited
number of valves restricts the validity of the results. Furthermore, other factors (different cells, low flow
conditioning before crimping) have to be further investigated. However, first results indicate a heavier
impact  of  the  crimping  process  than  previous  studies  suggest.  Nevertheless,  Schmidt  et  al.  (2010)
reported no thromboembolic event after crimping and delivering the valve  in vivo. Still, the crimping
process seems to disturb the cell-cell interaction of the first layer, the EC. Especially, when the use of
other scaffold material is considered for an in vivo use a viable, intact EC layer is important to reduce
thrombogenicity and calcification. Previous studies showed that an EC layer decreases calcification rate
and degeneration of the BHV (Jansson et  al.  2001; VeDepo et  al.  2016).  Furthermore, a cell  coated
homograft also enables growth and modification of the ECM. Seeded with the patient's own cells the
thrombogenicity as well as inflammation will be reduced. The slow degradation of the scaffold over time
and the production of new ECM from the autologous cells can create a durable heart valve, which is able
to grow. Especially younger patients will benefit from this solution. In younger patients degradation rate
of BHV is higher than in adult patients. Moreover, the gradual growth of the heart valve is not possible
and this subjects young patients to subsequent vale replacement surgeries over time. 
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7. Summary
To date an ideal heart valve prosthesis does not exist. Tissue engineering may enable the creation of an
optimal valve prosthesis. We evaluated the performance of such a tissue engineered valve and assessed
the cell layer integrity. In our study we wanted to know if the crimping process during a TAVI damages
the cell layer of a tissue engineered valve when put under perfusion. We used an aortic valve homograft
whose ECM structure provides ideal qualities in terms of mechanical stability and cell adhesion. After the
decellularization process, which decreases the immunogenic potential of the valve and facilitates cell
adhesion, we seeded cells from a different donor on the scaffold. The crimping process was performed
analogously to a TAVI procedure. The perfusion process was simulated using a bioreactor. After perfusion
we took samples for evaluation with immunohistology and SEM. 
After the recellularization 100 % of the wall was covered with FB as well as EC. After perfusion, samples
showed a loss of cell coating. The EC layer was reduced to an average of 10 %, the FB layer decreased to
65 %. While there was no difference in the EC layer on the leaflet's arterial and ventricular side, the FB
distribution was different. 70 % of the arterial side of the leaflet was covered with FB and 90  % of the
ventricular side. This difference may be attributed to the different flow conditions on the different sides
of the leaflet. The overall decrease in cell layer density implies a damage, which is done to the cell layer
during the crimping process. König et al. (2016) conducted a study, which demonstrated the damage to
the cells on a biohybrid valve after crimping. After perfusion, these dead cells disappeared from the
leaflets. These results further support our findings. 
A tissue engineered valve, which has to be implanted via the TAVI procedure, first has to withstand the
crimping procedure. Different approaches have to be considered to enhance the adherence of the cells
to the valve. A precondition phase may improve the attachment of the cells. Optimizing the crimping
procedure may be another option. Another approach would be the  in vivo endothelialization of the
valve.  Aubin  et  al.  (2016)  demonstrated  in  their  study  a  successful  in  vitro endothelialization  of
decellularized ovine pulmonary heart valves and aortic grafts. However, they failed to prove a significant
enhancement of  in vivo  endothelialization of the scaffolds. Further, platelet attachment, immune cell
activation and an excessive proliferation of smooth muscle cells has to be avoided. 
Tissue engineered  valves  are  a  promising  approach to overcome the shortcomings  of  the currently
available heart valve prostheses. Schmidt  et al. (2010) demonstrated in their experiment a successful
transapical implantation of a TEHV. They used a self-expandable nitinol stent to avoid the strain on the
leaflets  during  reexpansion  with  a  balloon.  However,  the  leaflet  surface  showed  only  partial
endothelialization and the pliability of the valve was reduced, most likely due to the absence of elastin. 
The current shortcomings of TEHV point out the need for further studies to improve cell attachment to
enable the implantation of a fully functional valve prosthesis. 
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3. Material
Cell isolation, Culturing and Perfusion
Materials Company REF-Number
6-Well plates TPP, Traisdingen, Switzerland 92412
BD Perfusion, Syringe with needle, 50 ml Becton  Dickinson  GmbH,  Heidelberg,
Germany
30038
Bottle Top Filters 0,2 µm Nalgene  Labware,  Thermo  Fisher  Scientific,
Roskilde, Denmark
595-4520
Bottle Top Filters 0,45 µm Nalgene  Labware,  Thermo  Fisher  Scientific,
Roskilde, Denmark
295-4545
Calcein AM – LIVE/DEAD Viability/Cytotoxicity
Kit
Invitrogen GmbH, Karlsruhe, Germany L3224
Cell culture flask 75 cm2, 162 cm2 Costar, Corning Incoporated, Corning, USA 3290,32
Cell culture flask, 12.5 cm2 Becton  Dickinson  GmbH,  Heidleberg,
Germany
353107
Collagenase Typ 2 CLS-2 (240 U/mg) Worthington  Biochemical
Corporation/CellSystems  GmbH,  St.
Katharinen, Germany
1476
Cryo Tube vials Nunc  GmbH  &  Co.  KG,  Langenselbold,
Germany
375418
Dimethyl Sulfoxide Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
D5879
Disposable Scalpel, 20 Feather  Safety  Razor  Co.,  LTD,  Medical
Division, Japan
02.001.30.020
Endothelial  Cell  Growth  Medium  +
Supplement Mix
Promocell GmbH, Heidelberg, Germany C-22010
Fetal Calf Serum (FCS) Lonza Group AG, Basel, Switzerland
Fibroblast Cell Growth Medium + Supplement
Mix
Promocell GmbH, Heidelberg, Germany C-23010
Gentamycin 10mg/ml Invitrogen GmbH, Karlsruhe, Germany 15750-037
Glutaraldehyd Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
49630
HCl (1N) Pharmacy,  University  of  Munich  Hospital,
Germany
L0306
Heparin 25.000 I.E./5 ml B. Braun Melsungen AG, Melsungen, Germany 126/317126/0403
Human serum albumin 20% ZLB Behring, Bern, Switzerland 300296
Medium 199 Earle Biochrom AG, Berlin, Germany F0665
Millex-GS filter unit (0,22 µm) Millipore Corporation, MA, USA SLGSO33SS
Mulitdirectional stopcock B. Braun Melsungen AG, Melsungen, Germany 16494C
Na-CaCO Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
20838
Neolus Luer Needle (0,9x70mm) Terumo Europe N.V., Leuven, Belgium 74203-02
PBS Dulbecco Biochrom AG, Berlin, Germany L1825
Penicillin 10 000 U/ml-Streptomycin 10 mg/ml
solution
Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
P4458
Perfusion Tube Set, Custom Product Medos Medizintechnik AG, Stolberg, Germany MEH82396
Culture Dishes, 35 mm diameter Nunc  GmbH  &  Co.  KG,  Langenselbold,
Germany
4021
PKH26GL Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
PKH26GL-1KT
99
Plain Drape, Secu-Drape Sengewald,  clinic  innovations,  Rohrdorf-
Thansau, Germany
504572
Plastic Jars R.E. Boll OHG, Munich, Germany 3500129
Plastic Screw Cup Storage Bottle, 500ml Costar, Corning Incorporated, Corning, USA 8393
PP Tube with screw cap, sterile, 50ml Greiner  Bio-One  GmbH,  Frickenhausen,
Germany
210261
PS Multipurpose Container, sterile, 30ml Greiner  Bio-One  GmbH,  Frickenhausen,
Germany
201170
Serological Pipettes 1, 2, 5, 10, 25ml Costar, Corning Incorporated, Corning, USA 4485, 4486, 4487, 4488, 4489
Surgical Gloves sterile Semperit GmbH, Vienna, Austria 822751805
Suture (3/0) Resorba, Nuernberg, Germany 91513
Syringe Filter (0,2µm) Nalgene, Rochester, NY, USA 19-2520
Transfer pipette 3,5ml Sarstedt AG & Co, Nuembrecht, Germany 86.1171.001
Trypan Blue Solution 0,4% Sigma  Aldrich  Chemi  GmbH,  Taufkirchen,
Germany
T8154
Trypsin – EDTA solution (10x) Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
T4174
Vessel cannules Medtronic GmbH, Meerbusch, Germany 30004
Water  for  Injection  Ph.  Eur.  Sterile  and
pyrogene-free
Fresenius Kabi AG, Bad Homburg, Germany 1080181
Wide Mouth jars 250ml Nalgene  Labware,  Thermo  Fisher  Scientific,
Roskilde, Denmark
2118-0008
Wide Mouth jars 950ml Nalgene  Labware,  Thermo  Fisher  Scientific,
Roskilde, Denmark
2118-0032
Solutions 
Name Composition Quantitiy
Storage Solution M199 
Penicillin-Streptomycin
20 ml
1 ml
Rinsing solution M199
Heparin 
Gentamycin
194 ml 
1 ml 
5 ml
Collagenase Solution EC Collagenase 240U
Human serum albumine
10 mg
8 ml
Collagenase Solution FB Collagenase 240U
Human serum albumine
20 ml
8 ml
Stopp solution M199
FCS 20%
500 ml 
125 ml 
Cryomedium (1,5 ml per vial) Cell growth medium
FCS 11 %
DMSO
1.05 ml
0.3 ml
0.45 ml
Endothelial cell growth medium Growth medium
Endothelial cell supplement
Fetal calf serum 6 %
Penicillin-Streptomycin
500 ml
10 ml
30 ml 
1 ml
Fibroblast cell growth medium Growth medium
Fibroblast supplement
Fetal calf serum
Penicillin-Streptomycin
500 ml
10 ml
55 ml (11 %)
1 ml
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Aortic Valve Storage, Decellularization and Recellularization
Materials Company REF-Number
2-Propanol >99% Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
085K3463
Amikacin Bristol GmbH, Munich, Germany
Amphotericin B Squibb  –  von  Heyden  GmbH,  Munich,
Germany
Ciprofloxacin Bayer AG, Leverkusen, Germany
Chloroform 99% Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
96596KS
Metronidazol Bayer AG, Leverkusen, Germany
Freezing bags Dr.  Marx  Medizintechnik  GmbH,  Gauting,
Munich
Sodiumdeoxycholate (SD) Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
031M0192V
Sodiumdodecylsulfate (SDS) Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
031M0028V
Vankomycin Lilly GmbH, Gießen, Germany
Solutions
Name Composition Quantity
Cryopreservation solution M 199
DMSO
200 ml
22.6 ml
Decellularisation Solution PBS
Sodiumdeoxycholate
Sodiumdodecylsulfat
500ml 
0.5 % (2.5 g)
0.5 % (2.5 g)
Storage Solution AV M199
Penicillin-Streptomycin
249 ml 
1 ml 
FIX II Aqua bidest
Glutaraldehyd
HCl (1N)
Na-CaCO
456 ml
43.5 ml
0.75 ml
5.65 g
Thawing solution M199
Penicillin-Streptomycin
500 ml
1 ml
Storage Soluation Decell M199
Penicillin/Streptomycin
500 ml
1 ml
Scanning Electron Microscopy
Materials Company REF-Number
Acetone for analysis Merck KgaA, Darmstadt, Germany 1.00014.5000
Ethanol 30, 50, 70 and 96 % Pharmacy,  University  of  Munich  Hospital,
Germany
Ethanol 99.9 % Pharmacy,  University  of  Munich  Hospital,
Germany
Specimen stubs, 12.5 mm Bal-Tec GmbH, Schalksmuehle, Germany G301Z
Carbon Adhesive Leit-Tabs Bal-Tec GmbH, Schalksmuehle, Germany G3347
Thermal  Paper  For  Mitsubishi  Video  Copy
Processor
Mitsubishi Electric Corporation, Tokyo, Japan K65HM-CE
Immunohistochemistry
Materials Company REF-Number
AEC Peroxidase Substrate Kit Vector Laboratories INC., California, USA SK-4200
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Anti Prolyl-4-Hydroxylase beta
Mouse IgG1
Acris Antibodies GmbH, Herford, Germany AF 0910-1
Anti Fibroblast, clone TE-7 0.1 mg/ml Millipore GmbH, Schwalbach/Ts., Germany CBL271
Anti-Fibronectin,  rabbit  polycolonal  serum
0.6 mg/ml
Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
F3648
Brij 35-Lösung Merck KgaA, Darmstadt, Germany 1.01894.0100
Buffer solution pH 10,00 Mettler Toledo GmbH, Giessen, Germany 513 340 056
Buffer solution pH 4,01 Mettler Toledo GmbH, Giessen, Germany 513 340 059
Cover glass, round, 20mm Zefa-Laborservice  GmbH,  Harthausen,
Germany
Z0121405
Culture slides 4-well Becton  Dickinson  GmbH,  Heidelberg,
Germany
354104
Culture slides 8-well Becton  Dickinson  GmbH,  Heidelberg,
Germany
354108
EDTA Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
E6635
EnVision rb/m Dako Deutschland GmbH, Hamburg, Germany K4061
Formalin 4% Microcos GmbH, Garching, Germany 29188
Hemalaun Merck KgaA, Darmstadt, Germany 1.09249
Hydrogen peroxide Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
21676-3
Monoclonal  Antibody  VE-Cadherin  CD  144
0.2 mg/ml
Beckmann Coulter Inc., Marseille, France PN IM1597
Monoclonal  Antibody,  MS  X,  Connexin  43
1 mg/ml
Millipore GmbH, Schwalbach/Ts., Germany MAB3067
Monoclonal  Mouse  Anti-Collagen,  Typ  IV
5.4 mg/ml
Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
C1926
Monoclonal  Mouse  Anti-Human Clone  CD31
Endothelial Cell 1:30
Dako Deutschland GmbH, Hamburg, Germany M0823
Monoclonal  Mouse  Anti-Human  Smooth
Muscle Actin 44 mg/ml
Dako Deutschland GmbH, Hamburg, Germany M0851
Monoclonal  Mouse  Anti-Human  Smooth
Muscle Myosin 954 mg/l
Dako Deutschland GmbH, Hamburg, Germany M3558
Slide Superfrost-OT Plus Schubert & Weiss-OMNILAB GmbH & Co. KG,
Munich, Germany
9161155
Swine Immunoglobulin Dako Deutschland GmbH, Hamburg, Germany X0906
Target Retrieval Solution 10x concentrate Dako Deutschland GmbH, Hamburg, Germany S1699
Tris-Base Merck KgaA, Darmstadt, Germany 1.08382
Tris-Borate-EDTA, Buffer, 10x concentrate Sigma  Aldrich  Chemie  GmbH,  Taufkirchen,
Germany
T4415-4L
Ultramount  Aqueous  Permanent  Mouting
Medium
Dako Deutschland GmbH, Hamburg, Germany S1964
Xylol Carl Roth GmbH + Co. KG, Karlsruhe, Germany 9713.3
Lab CD106/VCAM-1 AB-3 Mouse 200 µg/ml ThermoFischer Scientific, Waltham, USA MS-1101-P
Anti-ICAM-1, clone W-CAM-1 1:20 Millipore GmbH, Schwalbach/Ts., Germany MAB2130
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Equipments
3-D-Adjustable Table University of Applied Sciences, Munich, Germany
Air oxygen proportioner Tescan Corporation Minneapolis, Minnesota, USA
Analytical Balance, ABS 770 Gottl. Kern & Sohn GmbH, Balingen-Frommern, Germany
Transcatheter Balloon 2,0cm Edwards Lifesciences Corporation, Irvine, USA
Berlin Heart EXCOR® Adult Berlin Heart GmbH, Berlin, Germany 
Bio Photometer Eppendorf AG, Hamburg, Germany
Cell Seeding Device University of Munich Hospital, Munich, Germany
Centrifuge, 5804R Eppendorf AG, Hamburg, Germany
Centrifuge, Mikro 22R Hettich, Tuttlingen, Germany
Centrifuge, Rotina 46R Hettich, Tuttlingen, Germany
Clamp Forceps University of Munich Hospital, Munich, Germany
Cobalt-chromium stent (CoCr, NP35N) Curtsey of 
Crimper University of Munich Hospital, Munich, Germany
Critical Point Dryer, CPD 30 Bal-Tec GmbH, Schalksmuehle, Germany
Digital Camera, EOS 300 D Canon Inc., Japan
Dissecting Scissors University of Munich Hospital, Munich, Germany
Dressing Forceps University of Munich Hospital, Munich, Germany
Dry spinning equipment in clean room iTV-Denkendorf, Germany
Electrophoresis Power Supply, EPS 300 Pharmacia Biotech, Cambridge, England
Endoscope, Borescope BS-10 Voltcraft, Hirschau, Germany
Flow meter, HT311 Transonic Systems Inc., Stuttgart, Germany
Freezer -20°C, Comfort Plus Siemens, Munich, Germany
Frigocut 2700 Leica, Brensheim, Germany
Gel Electrophoresis Apparatus, Horizon 58 Life TechnologiesTM, California, USA
Glass jar with 3 luer connection Custom Product, Gaßner Glastechnik GmbH, Munich, Germany
Hegar Dilatator University of Munich Hospital, Munich, Germany
High speed CCD Camera PCO AG, Kelheim, Germany
Incubator, APT line TM CB Binder GmbH, Tuttlingen, Germany
Incubator, Hera Cell, Heraeus Kendro Laboratory Products, Hanau, Germany
Kidney Bowls University of Munich Hospital, Munich, Germany
Kryo 10 Planer PLC, Middlesex, United Kingdom
Lab Digital Water Bath, Julabo SW23 Kendro Laboratory Products, Hanau, Germany
Laboratory air pump, Laboport KNF Neuberger GmbH, Freiburg, Germany
Lamina Airflow, Hera Safe Kendro Laboratory Products, Hanau, Germany
Light microscope, Axiovert 35 Carl Zeiss MicroImaging GmbH, Göttingen, Germany
Low Shear Rheometer Rotovisco RV 100, Thermo Haake GmbH, Karlsruhe, Germany
Magnetic stirrers and hot plate IKA Works, Staufen, Germany
MicroAmp 96-Well Tray/Retainer Set Applied Biosystems Inc., California, USA
Microwave Siemens, Munich, Germany
Nalgene Nunc Cryo 1°C Freezing container Nalgene Labware, Thermo Fisher Scientific, Roskilde, Denmark
Neubauer improved counting chamber Brand GmbH + Co. KG, Wertheim, Germany
Paraffin Tissue Floating Bath, Round Model Medax GmbH & Co. KG, Rendsburg, Germany
Perfusor, Secura RS232 B. Braun Melsungen AG, Melsungen, Germany
pH-meter, inoLab WTW GmbH, Weilheim, Germany
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Pipetboy Eppendorf AG, Hamburg, Germany
Plastic bag sealer Polystar Rische + Herfurth GmbH, Hamburg, Germany
Pressure Amplifier, HBM Typ 3962 Hottinger Baldwin Messtechnik, Darmstadt, Germany
Pressure monitor, Sirecust 304 D Siemens, Munich, Germany
Pressure sensors, HBM 12926 Typ P11 Hottinger Baldwin Messtechnik, Darmstadt, Germany
Pressure transducer GOULD Statham, CA, USA
Pulsatile roller pump Stoeckert, Munich, Germany
Scanning electron microscope, Evo LS10 Zeiss, Oberkochen, Germany
Sequence detection system for Real-Time PCR, ABI PRISM 7700 Applied Biosystems Inc., California, USA
Signal connection box Data Translation GmbH, Bietigh, Germany
Single channel pipettes (10, 100, 200, 1000 µl) Eppendorf AG, Hamburg, Germany
Sputter Coater, SCD 50 Bal-Tec GmbH, Schalksmuehle, Germany
Tecplot software, Version 10 Amtec Engineering Inc., Houston-Texas, USA
Temperature sensor, ETS-D4 IKA Works, Staufen, Germany
UV-Transilluminator, Rainbow CCTV RMB92 Vilber Lourmat GmbH, Eberhardzell, Germany
Ventricle Assist Device MEDOS Medizintechnik AG, Stolberg, Germany
Video Copy Processor, P66DE Mitsubishi, Tokyo, Japan
Vortex-Mixer, MS1 Mini shaker IKA Works, Staufen, Germany
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